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A simple, precise "reaction rate" assay for plasma 
cholinesterase based on a succiny1choline substrate has 
been developed. 
It's ability to define individuals at risk of 
succiny1choline sensitivity and identify those who had 
experienced apnoea was superior to the previously best 
available assay. 
However it was not able to identify abnormal forms of 
cholinesterase which could hydrolyze conventional assay 
substrates but not succinylcholine. It was-concluded that 
if these forms exist their numbers are small. 
The failure to identify such cholinesterase types may have 
been because'the substrate concentration chosen for the 
assay was higher than that found"pharnacologically. 
However investigation of the kinetics of the 
succiny1choline-cholinesterase interaction showed that 
this was not the case. 
The assay was applied to the assessment of liver 
dysfunction and compared to three established methods was 
superior. All assays identified patients with severe liver 
disease but the succinylcholine-based one identified more 
patients with moderate/mild disease. 
The assay was also used to investigate the clinical 
observation that children require a higher dose of 
succiny1choline for muscle relaxation than adults. Infants 
were found to have higher succiny1choline activities than 
adults which is compatible with their relative resistance 
to the drug. 
Finally cholinesterase measurements were made, using a 
range of substrates including succinylcholine, in a 
variety of animal species. Results show that only when 
succiny1choline is used as the substrate for'the assay of 
cholinesterase does enzyme activity correlate with 
tolerance to it's muscle relaxant properties. 
The choice of procedure for the analysis of any 
biochemical variable depends on a number of criteria 
including ease of assay, precision, accuracy and cost; 
however the primary consideration should be the ability of 
the method to provide clinically useful information. Based 
on all these criteria, in particular the latter, 
succiny1choline must be considered as the substrate of 
choice. 
CONTENTS. 
CHAP= 1 INTRODUcrION: 
Literature Review and Aims. 
1.1 History 2-4, 
1.2 The chemical and physical nature 
of cholinesterase 4-17 
1.2.1 The relative molecular mass 4 
1.2.2 The structure and active site 7-9 
1.2.3 multiple forms of cholinesterase 
a) Isoenzymes 9-12 
b) Genetic variants 12-17 
1.3 The biochemical properties of 
cholinesterase 17-22 
1.3.1 Enzyme substrate interaction 17-20 
1.3.2 Inhibition and-activation 20-22 
1.4 The physiological properties of 
cholinesterase 22-25 
1.5 The clinical significance of plasma 
cholinesterase 26-34 
1.5.1 In disease 26-29 
1.5.2 In toxicology 29-30 
1.5.3 In succiny1choline apnoea 30-34 
1.6 Cholinesterase in animals 34-37 
1.7 measurement of plasma 37-43 
cholinesterase 
1.8 Aims 43-44 
CHAPTER 2 MATERIALS AND METHODS 
2.1 Materials 45-46 
2.2 Analytical methods 47-54 
2.2.1 Measurement of enzyire activity 47-50 
2.2.2 Ascription of cholinesterase 
genotype 50-52 
2.2.3 Preparation of icteric sera 52-53 
-2.2.4 Ultrafiltration of sera 53 2.2.5 Liver function tests 53-54 
2.3 Statistical methods 54-55 
CHAPTER-3 DEVELOPMENT OF A SUCCINYLCHOLINE-BASED 
ASSAY FOR SERUM CHOLINESTERASE 
Introduction 56-58 
3.1 Preliminary investigations 58 
3.2 Determination of the most approprate 
blank solution for use in the assay 58-59 
3.3 Investigation of linearity 59-60 
3.4 Calibration 60-61 
3.5 Investigation of the most 
appropriate substrate concentration 61-62 
3.6 Investigation of the effect of 
altering the concentrations of the 
components of the colour reagent 62-63 
3.7 The final f ornat of the method, 63-64 
3.8 Imprecision 64 
3.9 Investigation of interferences 64-66 
3.1Q Reference range 66 
Tables and Figures 66-79 
CHAPTER 4 THE EVALUATION OF THE SUCCINYLCHOLINE-BASED 
CHOLINESTERASE ASSAY FOR THE INVESTIGATION 
OF SUCCINYLCHOLINE INDUCED APNOEA 
Introduction 80 
4.1 Comparison of the succinylcholine- 
and propionylthiocholine activities 
of healthy phenotypically, usual 
individuals 80 
4.2 Comparison of the succiny1choline 
and propionylthiocholine activities 
- of individuals referred for assessment 
of cholinesterase status 81-82 
4.3 Comparison of succiny1choline and 
propionylthiocholine activities of 
samples from individuals with genetic 
abnormalities of cholinesterase 82-84 
4.4 Application of the succinylcholine- 
based assay to biochemically normal 
individuals with apnoea following 
treatment with succiny1choline 84-85 
4.5 Discussion 85-88 
Tables and Figures 89-104 
CHAPTER 5 INVESTIGATION OF THE KINETICS OF THE 
SUCCINYLCHOLINE-CHOLINESTERASE REACTION 
'USING 
THE NEWLY DESCRIBED ASSAY 
A. INVESTIGATION OF THE TYPE OF KINETICS 
EXHIBITED BY THE INTERACTION BETWEEN 
CHOLINESTERASE AND SUCCINYLCHOLINE 
Introduction 105 
5.1 Kinetic studies using the 
succiny1choline-based assay for serum 
cholinesterase 105-106 
5.2 Discussion 106-108 
B. COMPARISON OF THE Kml VALUE OBTAINED IN THIS 
STUDY WITH THOSE REPORTED IN THE LITERATURE 
Introduction 
5.3 Investigation of the 
calibration 
5.4 Studies of potential 
choliesterase in the 
5.5 Discussion 





assay system 109-110 
110-113 
114-125 
CHAPTM 6 THE SUCCINYLCHOLINE-BASED ASSAY IN LIVER 
DISEASE 
Introduction 126 
6.1 Patients 126-127 
6.2 Cholinesterase activities in patients 
with liver disease - 127-128 
6.3 Comparison of albumin and 
succiny1choline activity in patients 
with liver disease 128 
6.4 Discussion 128-129 
Tables and Figures 130-140 
CHAPTER 7 THE SUCCINYLCHOLINE-BASED ASSAY IN NEONATES 
AND CHILDREN 
Introduction 141-142 
7.1 Subjects 142 
7.2 Cholinesterase activities of subjects 
studied 142-143 
7.3 Discussion 143-145 
Tables and Figures 146-147 
CHAPTER 8 CHOLINESTERASE MEASUREMENTS ON ANIMALS - 
Introduction 148-149 
8.1 Blood samples and methods 149 
8.2 Studies on domestic animals 149-151 
8.3 Studies on zoo animals 151 
8.4 Discussion 151-155 
Tables and Figures 156-166 
CHAPTER 9 CONCLUSIONS 167-169 
REFERENCES. 
Table No Title Page No 
1.1 Nomenclature and organs of origin for 
cholinesterase and acetyl- 
cholinesterase 5 
1.2 Estimates of the relative molecular 
mass of the C4 courponent of human 
cholinesterase 6 
1.3 Approximate -- frequencies of 
cholinesterase genotypes in a 
Caucasian population 17 
3.1 Cholinesterase activities in 'serum 
samples taken from a volunteer before 
and after a fatty meal 67 
3.2 Cholinesterase activities in a serum 
sample before and after the addition 
of bilirubin 68 
3.3 Cholinesterase activities in a sample 
before and after haemlysis 69 
3.4 Cholinesterase activities in healthy 
phenotypically usual individuals 70 
4.1 Succinylcholine and propionyl- 
thiocholina (PTCI) activities in 
healthy El, homozygotes 89-90 
4.2 Comparison of the succiny1choline and 
propionylthiocholine (PTCI)-activities 
of 76 patients referred for routine 
investigation of cholinesterase status 91-92 
4.3 Succinylcholine and propionyl- - 
thiocholine activities in individuals 
with genetic abnormalities of 
cholinesterase 93-94 
4.4 Cholinesterase activities in 
biochemically normal patients with 
apnoea after treatment with 
succiny1choline 95-96 
4.5 Typical velocity versus substrat 
concentration results for an El 
homozygote demonstrating Michaelis- 
Menten kinetics 97 
4.6 Km and Wax values for healthy El u 
homozygotes and for patients with 
normal cholinesterase status but who 
developed apnoea following treatment 
-with succinylcholine 98 
5.1 Km and vmax values for the hydrolysis 
of succinylcholine by cholinesterase 
at Site 1 and Site 2 114 
5.2 Km values for succinylcholine and 
cholinesterase previously reported 115 
5.3 Investigation of the inhibition of 
cholinesterase by aminophenazone and 
phenol 116 
5.4 Km and Vmax values obtained after 
reducing the aminophenazone 
concentration - 117 
6.1 Full clinical details of patients with 
liver disease 130-133 
6.2 Cholinesterase activities in patients 
with liver disease 134-135 
6. 3 Cholinesterase activities expressed as 
- stundard deviations from the mean for 
El homozygotes and modified Childs 
grading for patients with liver 
disease 136-137 
6.4 Numbers of subjects with low 
cholinesterase values and their 
Child's grading 138 
7.1 Cholinesterase activities in neonates 
and infants 146 
8.1 Cholinesterase activities in domestic 
animals 156-159 
8.2 Cholinesterase activities in zoo 
animals 160-162 
Figure No. Title Page No 
3.1 Equivalents of" cholinesterase 
activity shown by spontaneous 
hydrolysis of a' range of 
succiny1choline concentrations 71 
3.2 The relationship between 
cholinesterase activity and reaction 
rate 72 
3.3 Absorbance produced by the addition 
of increasing amounts of choline 
chloride to the reaction mixture 73 
3.4 Cholinesterase activities in sera 
from an individual homozygous for 
the usual gene and one homozygous 
for the atypical gene 74 
3.5 Succinyl6oline activity measured 
using colour reagent with increasing 
aminophenazone concentration 75 
3.6 Succiny1choline activity measured 
using colour reagent with increasing 
peroxidase concentration 76 
3.7 Succinylcholine activity measured 
with colour reagent with ipCreasing 
choline oxidase concentration 77 
3.8 Succinylcholine activity measured 
using colour reagent with increasing 
phenol concentration 78 
3.9 Succinylcholine activities of 
healthy individuals homozygous for 
the usual gene 79 
4.1 Comparison of cholinesterasa 
activities of healthy El 
homozygotes rmasured using 
succiny1choline and propiony1choline 
substrates 99 
4.2 Comparison of enzyme activities of 
76 subjects referred for routine 
investigation of cholinesterase 
status 100 
4.3 Succinylcholine activities of'- 87 
subjects with unusual cholinesterase 
genotypes 101 
4.4 Propionylthiocholine 'activities of 
87 subjects with unusual 
cholinesterase genotypes 102' 
4.5 Graphs of substrate -concentration 
against velocity and its reciprocal 
for an individual homozygous for the 
usual gene 103 
4.6 Michaelis-MeUten constants in, 
healthy , El homozygotes and in 
patients normal by current 
biochemical criteria but who had 
experienced apnoea after treatment 
with succiny1choline 104 
5.1 Plot of velocity against log 
succiny1choline concentration for 
serum from three individuals 
homozygous for the usual 
cholinesterase gene 118 
5.2 Lineweaver-Burk plot for serum from 
one individual homozygous for the 
usual gene 119 
5.3 Plot of - velocity against log 
succinylcholine concentration for 
serum from an individual homozygous 
for the atypical cholinestdrase 120 
5.4 Lineweaver-Burk plot for the serum 
from an individual homozygous for 
the atypical gene 121 
5.5 Plot of velocity against log 
succinylcholine concentration for 
purified cholinesterase 122 
5.6 Lineweaver-Burk plot for purified 
cholinesterase 123 
5.7 Absorbance produced by the addition 
of increasing amounts of choline 
iodide to the reaction mixture 124 
5.8 Lineweaver-Burk plot for serum from 
one subject before and after 
reducing the aminophenazone 
concentration 125 
6.1 Cholinesterase activities measured 
using four substrates in patients 
with clinically graded liver disease 139 
6.2 Albumin concentration and 
succinylcholine activity in patients 
with clinically graded liver disease 140 
7.1 Cholinesterase activities in 
neonates and infants measured using 
succiny1choline I and 
propionylthiocholine as substrates 147 
8.1a Cholinesterase activities in 
domestic species expressed as a 
%age of the mean of the appropriate 
human reference range 163 
8.1b Cholinesterase activities in 
domestic species expressed as a %age 
of the mean of the appropriate human 
reference range 164 
8.2 The relationship between 
cholinesterase activity measured 
using conventional substrates and 
tolerance to succiny1choline in a 
range of species 165 
8.3 The relationship between 
cholinesterase activity masured 
with succiny1choline as the 
substrate and tolerance to 
succinylcholine in a range of 
species 166 
ABBREVIATIGNS 
All abbreviations are defined in the text. The 
cumulative list is given below: 
DFP 32P di-isopropylfluorophosphateý 
HPLC High performance liquid chromatography 
SD Standard deviation 
DTNB 5,5'-dithiobis-(2-nitrobenzoic acid) 
Tris [Tris-(hydroxymethyl)-aminomethaneI HCL 
DMSO Dimethylsulphoxide 
Km Michaelis-Menten constant 
Vmax Maximum velocity of enzyme substrate 
reaction 
PTCI Propionylthiocholine 
ECr Electroconvulsive therapy 
ACKNOWLEDGEMENTS. 
I would like to thank the following: 
My mother and father for their support throughout my 
acedemic career without whom I would never have been in a 
position to attempt this thesis. 
My supervisor Dr Robert Evans for his advice and help 
throughout the course of this project for which I am 
extremely grateful. 
For their gifts of samples: 
Dr Moss Horse Racing Forensic Laboratories 
Ltd., Newmarket, Suffolk. 
Mr M. S. Bain Veterinary Investigation Centre, 
Riseholme, Lincolnshire. 
Professor Kerr Department of Animal Physiology and 
Nutrition, University of Leeds. 
Dr C. Hawkey Wellcome Research Laboratories, 
London Zoo, Regents Park, L<)ndon. 
For advice on sections of the thesis: 
Dr J. McCormack, Biochemistry Department, University of 
Leeds and Dr S. Halford, Biochemistry Department, Bristol 
University for their advice on enzyme kinetics. 
Dr A. Hay, Department of Chemical Pathologyr University of 
Leeds for his advice on the animal work. 
The biochemists who worked in the Cholinesterase Research 
Unit, St. Jams's Hospital during the course of this 
project: 
Dr J McGinlay, Dr C. Rapier, Ms A. Walker, Ms K. Bowden 
and Ms J. O'Callaghan 
for their scientific assistance and companionship. 
Dr R. Jones for computer programs which made the writing 
of this thesis considerably easier. 
Finally my husband Paul for his unfailing support and fine 
scientific advice. 
PUBLICATIONS RESULTING FROM KRK CCNIULINED WITHIN THIS 
THESIS. 
FAYE S. A. and EVANS R. T. (19861 
Is succiny1choline the substrate of choice in the 
measurement of cholinesterase activity? 
Clinical Chemistry 32,1477-1480. 
FAYE S. A. and EVANS R. T. (19881 
Differences in the response of hurmns and dogs to 
succinylcholine. 
Anesthesiology 68,471-472. 
FAYE S. A., BANNISrER P. and EVANS R. T. [19881 
Cholinesterase measurement in chronic liver disease. A 
succiny1choline-based assay is most clinically useful. 
Annals of Clinical'Biochemistry 25, Supplement, 79-80. 
1 
CHAPTER 1 INTRODUCTION 
Literature'review and aims 
2 
1.1 Hisim. 
" The evanescence of the effect, and the regularity of 
its reproduction with sucessive doses, which, as we shall 
see, are characteristic of all the actions of acetyl- 
choline, may be connected, with some probability, with the 
readiness with which the ester is hydrolysed into its 
relatively inert constituents, choline and acetic 
acid ......... In -the blood at body temperature it seems 
not improbable that an esterase contributes to the removal 
of the active ester from the circulationt and the 
restoration of the original condition of sensitiveness. 0 
DALE 1914 
Dale in 1914, with this statement concerning the action of 
acetylcholine, -first predicted the existence of 
cholinesterase. Experimental support for his view was 
provided by Loewi and Navratil seven years later when they 
showed that if eserine was present the effect of 
acetylcholine on frogs heart was prolonged (Loewi and 
Navratil 1921]. They attributed this result to the 
inhibition, by eserine, of the enzyme normally responsible 
for the degredation of acetylcholine. 
It was not until 1932 that the f irst crude extract of 
cholinesterase was prepared from horse serum [Stedman, 
Stedman and Easson 19321. Between 1940 and 1943 it was 
established that there were two cholinesterases in the 
body, one present in erythrocytest the other in serum, 
differing in sensitivity, specificity and other 
properties. This was first shown by Alles and Hawes C 19401 
who compared their properties. They showed that 
erythrocyte cholinesterase was several times more active 
than the serum enzyme at low acetylcholine concentrations. 
3 
However, as substrate concentration was increased the 
erythrocyte enzyme was inhibited whilst serum enzyme 
activity increased throughout the range of concentrations 
studied. This work was confirmed and extended by Mendel 
and his colleagues [Mendel and Rudney 1943; Mendel and 
munde 11 1 943, Mendel, Mundell and Rudney 19431. They found 
that a relatively small degree of purification of 
erythrocyte cholinesterase deprived it of the ability to 
hydrolyse the aliphatic esters, tributyrin and 
nethylbutyrate, whereas a much higher degree of 
purification of the enzyme from horse serum and dog 
pancreas did not. They named the two enzymes 'true" and 
wpseudo" cholinesterase respectively. Soon afterwards they 
found that henzoylcholine was hydrolysed by "pseudo" 
cholinesterase tut not by "true" cholinesterase. The 
reverse was true of acetyl-B-mthylcholine. Consequently 
they were able to use this pair of substrates as a means 
of identifying the two kinds of cholinesterase in blood 
and tissues. 
The work of Mendel and colleagues has not escaped 
criticism. The use of benzoylcholine and acetyl-B- 
methylcholine to define pseudo- or serum cholinesterases 
as distinct from true or acety1cholinesterases has caused 
confusion as they are not the preferred substrates for 
cholinesterase and acety1cholinesterase respectively in 
all species (Myers 19531. Despite this and controversy 
concerning the use of the term "pseudow [Glick 19481, the 
4 
work of Mendel and colleagues was important since it 
emphaiis'ed the concept'of the-exi I stence of two types 11 of 
cholinesterase, one specific for acetylcholine and a few 
closely related choline estersp the other capable of 
hydrolysing both choline esters and those of aliphatic 
acids. 
The terrm "true" and "pseudo" cholinesterase have now been 
replaced by more modern nomenclature. A summary of the 
terminology relevant to the two enzyý, nes appears in Table 
2 THE CM24ICAL AND PHYSICAL NATURE or CEK)LINESrERASE. 
most of the information concerning the nature 'of 
cholinesterase has come from experiments on the enzý7es 
present in horse or human serum. Wide species differences 
in cholinesterase do occur and will be discussed later. 
Human cholinesterase is a glycoprotein. Electrcphoretic 
studies [Surgenor et al. 19491 indicate that it is anck-2 
globulin. 
1.2.1 The Relative Molecular Mass: 
The relative molecular mass of cholinesterase is high, 
approximately 350,000 daltons, suggesting a complex 
protein molecule with multiple subunit structure. The 
molecular weight of the purified enzyme has been 




NORMLATURE AND - CRUM 
OF CRIGIN FOR,, CHOLINESMASE 
j7M ACETYLCHOLINEgrERASE. 
Systematic Enzyme Accepted Historical Principle 
name cor. nission trivial trivial sites of 
number name name distribution 
in mammals 
Acetyl- EC 3.1.1.7 Acetyl- Specific Grey matter 
choline cholin- cholinesteras e of central 
acetyl- esterase true cholin- nervous 
hydrolase esterase, E- system, 





Acylcholine EC 3.1.1.8 Cholin- Non specific Intestinal 
acyl- esterase cholin- mucosa, 
hydrolase esterase, liver, plasma, 
pseudo white matter 




. esterase, S-type cholin- 
esterase. 
(Evans 19861 
** Suggested by the Commission on Biochemical Nomenclature 
of the International Union of Pure and Applied Chemistry 
and the International Union of Biochemistry [19731 and 





TER M ASS OF TEE C4 
COMP(POM OF CHOLINESEERASE. 
VALUE METHOD AUTHORS 
(Daltons) 
3481'000 Ultracentrifugation: Haupt et al'. 
sedimentation equilibrium 1966 
366,000 Ultracentrifugation in a Das and Liddell 
density gradient and gel 1970& 
filtration 
280,000 Sephadex gel filtration La Du and' 
Snady 1971 
345,000 Ultracentrifugation: Muensch, Goedde 
sedimentation equilibrium and Yoshida 
1976 
ý371,000 
Sepharose 6B gel filtration: Pickard 1976 
acrylamide electrophoreisis 
342,136 Sequencing: HPLC purification Lockridge et al. 




1.2.2 The Structure and Active Site: 
Muensch, Goedde and Yoshida [1976) first determined the 
component amino acids of cholinesterase and also estimated 
the carbohydrate content. They found it to be 24.5% in 
agreer*nt with the 23.9% reported by Haupt et al. (19661. 
Cnly recently has a complete sequence of the protein 
portion of the molecule been performed using Edman 
degredation of purified peptides [Lockridge et al. 19871. 
This work showed that the protein contains 574 amino- 
acids per subunit and confirmed previous reports that 
human cholinesterase is a tetramer of identical subunits 
[Lockridge and La Du 1978, Lockridge, Eckerson and La Du 
19791. Each subunit has 9 carbohydrate chains, terminating 
in sialic acid and attached to the protein through 
asparagine. 
If the sialic acid residues are split off, using bacterial 
neuraminidase (EC 3.2.1.8), the electrophoretic mobility 
of cholinesterase is altered, it migrates with the serum 
S-globulins rather than the ý(-globulins [Svensmark 19611 
and the isoelectric point of the enzyme is changed from 
less than 3 to 7 [Svensmark and Kristensen 1963]. However 
despite this, neuraminidase treated human cholinesterase 
retains it's hydrolytic activity and it ,s inhibitory 
characteristics with respect to dibucaine and fluoride 
[Echobichon and Kalow 19631. The carbohydrate portion of 
the molecule therefore cannot be involved in the active 
site. 
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The nature of the active site has been extensively studied 
(Brown et al. 19811. It possesses anionic and esteratic 
subsites and hydrophobic areas. The anionic site 
determines specificity with respect to the choline 
portion of the substrate while hydrolysis of the ester 
tond of the substrate occurs at the esteratic site. The 
role of the hydrophobic areas is unclear but it has been 
proposed that differences in their length and structure 
riay- account for the differentý kinetic properties of 
cholinesterase and acety1cholinesterase [Kabachnik et al. 
1970]. The nature of the esteratic subsite has been more 
fully elucidated- than- the 'anionic subsite. An 
organophosphate, [32p I di-isopropy1fluorophosphate (DFP)F' 
which ' binds irreversibly at the esteratic site of 
cholinesterase, has been used to elucidate the structures 
involved in catalytic activity and has indicated that 
serine has an active'role [jansz, Brons and Warringa 
19591. -- However it has been pointed out that the pK Of 
serine is not consistant with the pH optimum of 
cholinesteraser pH 8 [Bergman et'' al. 19561'. ' Cnly the 
imidazole -ring of histidinel' pK 6.95, has a pK in the 
range required. However the peptide sequence at the active 
site is similar to other'enzymes where serine does have-an 
active role to play in the -catalytic process [Blow, 
Birktoft and Hartley 19691. In such enzymes both histidine 
and serine are in close association. In 1986'the active 
site was sequenced and the'presence of both these amino 
acids was confirmed (Lockridge and La Du-19861. 
9 
The number of active sites per enzyme molecule has been 
variously estimated at either two [Muensch, Goedde and 
Yoshida 19761 or three [Yoshida and Motulsky 19691 using a 
DFP titration technique. However using a different method 
in which a carbamylester was hydrolysed to a fluorescent 
product, four active sites were demonstrated by Lockridge 
and La Du (19781. 
1.2.3 Multiple forms of cholinesterase: 
a) Isoenzymes: 
Human serum cholinesterase can be separated into at least 
four components which appear to be isoenzITes since ithey 
have similar substrate specificity and inhibitor 
susceptibility [La Motta and Woronick 19711. 
Harris, Hopkinson and Robson [19621 found four bands (Cl- 
CO using two-dimensic-1 electrophoresis with paper and 
starch gel. Cl migrated furthest towards the anode and C4, 
the major component with approximately 80% of enzyme 
activity, moved least. most workers have adopted this 
numbering system, so that the major isoenzymes of 
cholinesterase are numbered consecutively, with the form 
migrating furthest being designated one. Unfortunately 
there are two sets of symbols for the electrophoretic 
bands of the enzyme; Cl-C4 (Harris, Hopkinson and rcbson 
19621 and ChEl-ChE5 (La Mottal McComb and Wetstone 1965]. 
Cl-C3 are identical to ChEl-ChE3 but C4 is identified with 
ChE4 and 5. Using polyacrylamide gel which gives better 
resolution than starch gel, more cholinesterase bands have 
10 
been identified. Juhl [19681 demonstrated 12 bands 
although other workers using similar techniques found 
rather less (Gaffney 1970, Das and Liddell 19701. 
Staining techniques can influence the number of isoenzymes 
detected, e. g. more bands will be revealed by the use of 
nonspecific esterase stains than with butyrylthiocholine 
which is specific for serum cholinesterase. However Juhl 
used butyrylthiocholine as the substrate for staining so 
it is difficult to explain these divergent results. 
La Motta, McComb and Wetstone (1965] showed that the 
isoenzýmes of cholinesterase could he interconverted 
during procedures such as ammonium sulphate precipitation 
followed by resolubilisation or dialysis against 
polyvinylpyrollidone. It thus seems that preparative 
-methods can influence the number of bands observed. it 
can be difficult therefore to establish which bands 
represent genuine naturally occuring isoenzymes and which 
are experimental artifacts. 
Following storage of the enzyme, extra "storage" bands 
appear which migrate close to the major- component. It is 
thought that they derive from the breakdown of the C4 
component [Harris, Hopkinson and Robson 19621. 
Gel filtration on sephadex G-200 showed C4 to have the 
highest molecular weight and the others to have decreasing 
molecular weight in the order C31 C2j C1 [Harris and 
Robson 19631. La Mottal Woronick and Reinfrank (19701 
determined the relative molecular masses of the isoenzymes 
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by ultracentrifugation in a sucrose gradient. They found 
values as follows; CbEl 82,000, ChE2 110,000, ChE3 
170,000, ChE4 200,000, ChE5 260,000. other workers have 
confirmed the values for Cl (ChEl): 86,000 [Boutin and 
Brodeur 1971) and 85,000 [Muenscht Goedde and Yoshida 
19761 but have found higher values for C4: 348,000 (Boutin 
and Brodeur 1971] and 345,000 [Muensch, Goedde and Yoshida 
19761. 
Several explanations have been put forward to account for 
the demonstration of m1tiple molecular forms of 
cholinesterase. They include variation in the amounts of 
sialic acid or partial breakdown of the molecule by 
proteolysis (Muensch, Goedde and Yoshida 1976]. There is 
some evidence that the heterogeneity of plasma 
cholinesterase reflects reversible polymerisation of 
protein subunits (La Motta, Woronick and Reinfrank 19701. 
Boutin and Brodeur were similarly of the opinion that 
interconversions occur in vitro, but expressed 
reservations about their occurrence in vivo. other 
evidence compatible with La Motta's proposals arises from 
work in which in vitro treatments, including ultrasonic 
vibration (Dubbs 19661, the action of urea [Augustinsson 
1973], freezing and thawing and treatment With sulphyryl 
reagents (Muensch, Goedde and Yoshida 19761, have been 
shown to alter the electrophoretic migration of 
cholinesterase. By such means the major component of the 
enzyme can be split into enzymatically active bands with 
electrophoretic mobilities corresponding to those of other 
12 
isoenzymes. 
b) Genetic variants of cholinesterase: 
These were first recognised following the clinical use of 
the muscle relaxant, succinylcholine. This drug is a 
depolarising neuromuscular blocking agent and has a short 
duration of action due to it's rapid hydrolysis by plasma 
cholinesterase. Succinylcholine was introduced into 
clinical practice in 1951 and one year later it was 
observed that some individuals suffered a prolonged 
reaction to it. These early cases of sensitivity were all 
thought to be due to impaired hepatic synthesis of 
cholinesterase since low levels of the enzyme were often 
found in patients who recovered slowly from 
succinylcholine (Bourne, Collier and Somers 1952 and Evans 
et al. 1952]. They therefore suggested that the drug 
should not be given in conditions where cholinesterase 
might be expected to be low, such as liver disease, severe 
anaemia, malnutrition or following organophosphate 
poisoning. Subsequently however, several cases were 
described in which there was no evidence for such 
conditions [Bourne 1953, Forbat, Lehmann and Silk 19531. 
It was Forbat, Lehmann and Silk (19531 who first suggested 
that there could be a hereditary basis for sensitivity but 
it was the work of Kalow and his colleagues (1957-1959] 
which confirmed it. 
Kalow and Gunn (19571 showed that cholinesterase from 
affected patients was abnormal. It did not appear to 
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hydrolyse succiny1choline in vivo or in vitro and it was 
unusually resistant to inhibition by the local anaesthetic 
dibucaine (Nupercaine). Using the percentage inhibition of 
the enzyme in the presence of a fixed concentration of 
dibucaine under standard conditions# the "dibucaine 
number" [Kalow and Genest 19571, Kalow and Staron (19571 
divided people into three groups, each possessing two 
allelic co-dominant genes for cholinesterase. Those 
homozygous for the usual enzyme form, El u El U, dibucaine 
number >70, those heterozygous for the usual and atypical 
forms, EluEla , dibucaine number 40-70 and those hanozygous 
for the atypical form, El a El a, dibucaine number <20. 
Individuals sensitive to succiny1choline were those 
homozygous for the atypical form of the enzyme, the 
product of a gene other than that found in unaffected 
persons (Kalow 19591. 
The results of work with dibucaine stimulated the search 
for inhibitors of cholinesterase which might help identify 
other genetic variants of the enzyme. In 1961 inhibition 
with fluoride led to the descript ion of the fluoride 
f 
resistant gene (El [Harris and Whittaker 19611. Other 
inhibitors have been studied including chloride (Harris 
and Whittaker 19631, Scoline (McComb, La Motta and 
ýýtstone 1965] and butanol [Whittaker 19681 but their use 
has not led to the discovery of further variants. 
Following the investigation of some families of 'atypical" 
individuals, anomalies were found. First degree relatives 
of "atypical* individuals appeared to have "usualu 
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cholinesterase [Kalow and Staron 19571. This suggested 
that there were a number of allelic genes for "usual" 
cholinesterase each determining it's production at a 
different rate, the extreme of which being an allele 
producing no cholinesterase activity at all. Confirmation 
of the existence of such a gene came in 1962 when a 
succinylcholine sensitive individual was described in whom 
cholinesterase activity was undetectable. It was proposed 
that the patient was homozygouý for the "silent" gene 
(Liddell, Lehmann and Silk 1962). 
In 1976 another allele at the cholinesterase locus was 
described, the J variant (Garry et al. 19761. This variant 
causes reduction of the number of *usual" molecules by 
approximately 66% so that El u El] heterozygotes have 
inhibitor numbers indistinguishable from El U homozygotes 
but reduced enzyme activity. It is unusual since it can 
only be identified with certainty when it occurs in 
combination with the atypical or fluoride resistant 
cholinesterase forms. It then gives rise to inhibitor 
numbers different from those of other known genotypes. Two 
years after the desciption of the J variant, the K form 
was discovered. Similarly it can only be recognised when 
uk in conjunction with the atypical gene. In El El 
heterozygotes it causes reduction in the number of usual 
enzyme molecules by about 33% but, like the J variant, it 
is not known whether this is due to decreased synthesis or 
increased degredation [Rubinsteint Dietz and Lubrano, 
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19781. 
Recently Whittaker has postulated the existence of another 
new variant, the H (Hamersmith) form. This variant was 
associated with a marked reduction in enzyme activity in 
EluElh heterozygotes and inhibition characteristics 
indicative of the El u Elu genotype. Ela El heterozygotes 
however were found to have unusual inhibition 
characteris tics with Ro 02-0683, the dimethylcarbamate of 
(2-hydroxy-5-phenylbenzyl) trimethylarnmonium bromide. 
These observations have not yet been confirmed. 
The frequencies with which the different cholinesterase 
genotypes occur varies with the population studied. The 
frequency of the El a gene is highest amongst Caucasian 
peoples whereas it has not teen detected among certain 
groups of Negroes and East Asians. The El 
f 
gene,, which is 
rare in most populationst was found with a high frequency 
among a group of Punjabis and certain Bantu tri bes. The 
silent gene, also uncommon amongst most populations, 
occurs with a high frequency in some groups of Alaskan 
Eskimoes [Brown et al. 1981]. Table 1.3 shows the 
frequency of the different genotypes in a Caucasian 
population. 
All variants previously described derive from allelic 
genes occuring at a locus designated El [Motulsky 1964]. 
Another variant has been reported characterised by the 
production of an extra enzyme component, migrating more 
Slowly than the C4 hand on starch gel electrophoresis 
[Harris, Hopkinson and Fýobson 19621. It was designated c5. 
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The gene which determines the production of the c5 
component occurs at a locus designated E2 in accordance 
with the motulsky system of nomenclature. Approximately 
10% of caucasians carry an E2 allelle which specifies the 
production of the C5 component and these have 
approximately 30% more plasma cholinesterase activity than 
those without the C5 band. 
Another type of cholinesterase which may be identified by 
it's electrophoretic characteristics is the Cynthiana 
variant, first described by Neitlich (1966]. 
_ 
He measured 
cholinesterase activities in a population of male military 
personnel and found one individual with an activity 
consistantly three times the mean. A study of the 
subject's immediate family indicated other affected 
relatives, all of whom showed an additiorial intense band 
on polyacrylamide gel electrophoresis. The extra band 
migrated more slowly than the C5 band (Yoshida and 
Motulsky 19691. The locus for the Cynthiana. gene has not 
yet been determined. The condition is rare, only two 
other affected families have been reported [Delbruck and 
Henkel 19791. They confirmed the quantitative and 
structural differences observed previously. 
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TNKZ 1.3 
APPROXIMATE FREQUENCIES OF QHOLINESTERAS QMLOTYPES LIN 
CAUCASIAN POPULATION. 
Genotype Frequency 
El u El u 95% 
El 
u 
El f 1 in 30 EluEl s 
1 in 200 
El El 1 in 220 
El f 71 f 1 in 19,000 El f El s 
1 in 160,000 
El a 
El 1 in 170fOOO 
El a 




1 in 20,000 
El a 
El 1 in 100,000 
El El. 
a 3 
1 in 250 
El E1 Unknown perhaps 1 in 200,000 
(Evans 19861 
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1.3 'THE BICCEBUCAL PROPERNES OF CWLIMSITF-ASE. 
1.3.1 Enzyme-Substrate Interaction. 
Plasma cholinesterase is a hydrolase which, under optimal 
conditions, catalyses the hydrolysis of choline and 
thiocholine esters at a higher rate than that of other 
esters. Using a homologous series of esters of choline it 
has been shown that butyrylcholine is the optimal 
substrate for usual human plasma cholinesterase and that 
pentanoy1choline shows the highest ý; Imx for the atypical 
enzyme (Davies, Marton and Kalow 1960]. Subsequent studies 
have shown that the order of the relative rates of 
hydrolysis by the usual enzyme was butyryl> valyryl> 
propionyl> acetyl> -ý-ethylbutyryl> a-irethylbutyryl [Sekul, ' 
Holland and Breland 19621. These workers have also shown 
that the introduction of a double bond at the I 
position in the alkyl group of choline esters reduces the 
rate of hydrolysis of the ester compared to that of the 
corresponding saturated alkyl ester. A double bond at any 
other position appears to have a less predictable effect. 
Substitution of an alkyl group at the c4-position in the 
unsaturated acid moiety of a choline ester causes an 
additional reduction in the rate of hydrolysis. 
Indirect evidence suggests that cholinesterase interacts 
with substrates 'by first forming an enzyme substrate 
complex which enables the serine hydroxyl group at the 
esteratic site to become acylated., The acylated group can 
then' react with any nucleophyllic reagent to regenerate 
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the f ree enzyme. This can be represented schematically as 
f ollows: 
EH + XY 
kl 








[Brown et al. 19811 
where EH represents cholinesterase (H belonging to the 
hydroxyl group of the serine residue present at the 
esteratic active site) and xy the substrate. The rate 
constants are kl, k-1, k2 and U, (k-1 <<< k2) 
The rate constant k2 determines the rate of acylation and 
U that of deacylation. The rate limiting step is the 
formation of the acylated enzyme. Deacylation is very fast 
making it difficult to detect the acyl enzyme by direct 
observation. 
Studies on the kinetics of cholinesterase have shown that 
it does not always obey Michael is-Menten kinetics. 
Inhibition is observed at high substrate concentrations 
with halogenated cholines [Sastry and Chiou 19681, 
benzoylcholine [Berry 19601, acetylsalicylcholine 
(Augustinsson 19481 and lactoylcholine [Sastry and White 
19681 but not with either acetyl or butyrylcholine [Brown 
et al. 1981] or with thiocholine esters (Wetherall- and 
French, 1986]. The latter workers showed that there is a 
further, increase in enzyme activity at high thiocholine 
ester concentrations. This. has also been shown for 
butyrylcholine [Hastings 1966). These observations have 
20 
been interpreted in several ways,, 
a) that there are two enzymes, present [Heilbron , 1958, 
Berry 1960] 
b) that -the enzyme is activated at high substrate 
concentration [Hastings 19661 
c) that there exists, a modifier or an allosteric site 
(Main 19831. 
1.3.2 Inhibition and Activation. 
Inhibitors of cholinesterase can be divided into two 
classes: 
a) Those acting reversibly, forming non-covalent bonds. 
b) Those acting irreversibly by the formation of covalent 
bonds. 
many reversihle inhibitors contain a quaternary anmnium 
group, for example neostigmine. The posftively charged 
nitrogen of such compounds is attracted to the negatively 
charged anionic site of the enzyme. inhibitors are also 
bound at this site by coulombic forces which may be 
augmented by Van der Waals attraction of the alkyl groups 
to hydrophobic areas near the anionic site [Brown et al. 
19811. Bis quaternary ammonium compounds, for example, 
pancuronium and succinylcholine are also reversible 
inhibitors of cholinesterase. on a mole for mole basis 
they have been found to be twice as potent as the simple 
quaternary anmnium compounds (Main 19761. other 
clinically interesting reversible inhibitors of 
cholinesterase are fluoride and dibucaine. Inhibition by 
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the fluoride ion follows complex kinetics [Heilbron 19651 
the mechanism of which is yet to be resolved. Dibucaine 
has a tertiary amine group and therefore acts in a 
similar way to quaternary ammonium compounds. 
Irreversible inhibitors react with the hydroxyl group of 
serine at the active site of cholinesterase. They bind at 
the same site as true substrates but bind covalently to 
form acyl-enzyme complexes which are resistant to 
hydrolysis [Brown et al. 19811. This group of inhibitors 
includes the organophosphates and carbamates. 
other substances capable of altering cholinesterase 
activity exist which do not fit into the above catagories, 
notably n-butanol. Whittaker studied the effects of alkyl- 
alchohols on human serum (1968a]. moderate alcohol 
concentrations activated the usual enzymd and only high 
concentrations caused irreversible inactivation due to 
denaturation. The atýpical enzyme was more readily 
inactivated and therefore alkyl-alcohols were advocated as 
a means of differentiating cholinesterase variants. It was 
claimed that new phenotypes could be recognised using n- 
butanol [Whittaker 1968b] but this has not been 
substantiated. 
Several compounds have been shown to enhance the 
hydrolysis of substrates by human cholinesterase. Erdos 
and co-workers using benzoylcholine and procaine 
demonstrated activation by tryptamine and histamine [Erdos 
et al. 19571, quaternary ammonium compounds JErdos et 
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al. 1958] and a series of narcotic analgesics [Erdos et al. 
19591. other compounds reported to activate cholinesterase 
include divalent cations (Hoftsee 19601, glutathione and 
pilocarpine [Keeser 19381. 
1.4 PE[YSIOU)GICAL PRMRTIES OF CBMINESTERASE. - 
In a normal healthy population the range of cholinesterase 
activities is wide but values within an individual show 
little variation. The main factors affecting 
cholinesterase activity are age, sex and pregnancy. 
There is controversy in the literature concerning 
cholinesterase levels at birth. Zsigmund and Downs [19711 
reported low levels of cholinesterase, approximately 50% 
those of adults in term neonates and infants up to 6 
months. Mirakur,, Elliot and Lavery (19841 and Strauss and 
Modanlou [19861 reported levels equivalent to that of 
adults in term neonates although they did report a 
transiently low activity in preterm neonates. Adult levels 
are achieved at the time of puberty and probably remain 
constant thereafter,, although some studies have noted 
further slight changes, either an increase [Propert and 
Brackenridge 1976] or a decrease [Kalow and Gunn 19581. A 
number of workers have shown sex differences, with higher 
activities in men than in women (Sidell and Kaminskis 
1975, Propert and Brackenridge 19761. There have been 
conflicting reports of the effects of pregnancy on plasma 
cholinesterase levels. Some workers have found no 
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difference between pregnant and non pregnant women (Meade 
and Rosalki 1963, Rimbach and Dacic 19631 whereas others 
have found lower activities in pregnant women 
[Tourtellotte and Odell 1950, Robertson 19661. A large 
study by Evans and Wroe (19801 has indicated that there is 
a fall in cholinesterase during the first trimester to 
levels which remained constant for the rest of pregnancy 
but with a further fall in the seven days following 
delivery. 
Despite the wide tissue distribution of cholinesterase in 
man [Silver 19741 there is controversy concerning it's 
physiological function. Healthy individuals exist who have 
no detectable cholinesterase activity which suggests 
either that it ,s role is not essential or that there is an 
alternative metabolic pathway which bypasses 
cholinesterase. 
Cholinesterase is found in the white matter of the central 
and peripheral nervous system in both man and animals, in 
close association with the acety1cholinesterase of the 
grey matter (Ord and Thompson 1952]. The function of 
acety1cholinesterase is to terminate the action of 
acetylcholine at all sites of cholinergic transmission and 
cholinesterase has been linked with this. Acetylcholine in 
high concentrations inhibits acetylchol ineste rase but not 
cholinesterase. Lehmann and Silk (19531 suggested that the 
function of cholinesterase may be protective, hydrolysing 
acetylcholine when it reaches concentrations sufficient to 
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inhibit acetylcholinesterase. In addition theories have 
been advanced that cholinesterase is a precursor of 
acety1cholinesterase [Koelle, Koelle and Smyrl 1973) and 
that it is involved in controlling plasma choline and 
acetylcholine levels [Funnell and Oliver 19651. 
Clitherow, Mitchard and Harper [19631 proposed that 
cholinesterase may be responsible for the breakdown of 
toxic choline esters arising from lipid or intestinal 
metabolism. However no evidence exists for the presence of 
toxic quantities of choline esters in human plasma or 
tissues. 
More recently there has been increasing interest in the 
relationship between cholinesterase and lipoproteins. 
Lawrence and Melnick (19611, after histochemical, 
inmnoelectrophoretic and quantitative studies, showed an 
association of cholinesterase with ý-lipoproteins. They 
suggested that the cholinesterase -lipoprotein complex 
existed for the purpose of transporting cholinesterase in 
an inactive form and that the union was a physical rather 
than a chemical one since it could easily be disrupted by 
physical means. This work was supported by that of Dubts 
[19661 who observed increased cholinesterase activity 
after ultrasonication of human serum. However work by 
Kutty and colleagues [1973-19801 has indicated that the 
relationship is an active one and that the association 
between cholinesterase and '-lipoprotein is a chemical 
one. Kuttyr Rowden and Cox [19731 provided evidence that 
cholinesterase interacts with the phosphocholine site of 
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the lecithin of lipoprotein and postulated that ý'it was 
there for the purpose of stabilising ý -lipoprotein. 
Support for this proposal came from studies. 
, 
using 
cholinesterase inhibitors which showed that changes in - 
lipoprotein paralleled those of cholinesterase after the 
ingestion of an organophosphate [Kutty et al 1975] and 
that neostigmine decreased the incorporation of tritiated 
lysine into -lipoprotein [Kutty, Redheendran and Murphy 
19771. 
A relationship between cholinesterase and 15 -lipoprotein 
undoubtedly exists, whether chemical or physical, 
-since 
an 
increase in plasTra cholinesterase has been noted in 
conditions associated with abnormal lipid metaLolism, in 
hyperlipoproteinaemia (Cucuianu et al 19751, obesity 
[Cucuianu, Popescu and Haragus 19681 and nephrotic 
syndrome (Way, Hutton and Kutty 19751 and may therefore be 
of clinical significance. 
4 
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1.5 THE. CLINICAL SIGNIFICANCE OF PLASMA CHOLINESTERASE. 
1.5.1 In disease: 
Since cholinesterase is synthesised in the liver the 
amount of enzyme appearing in the plasma is dependant 
both upon normal liver function and an adequate delivery 
of amino acids. Measurement of cholinesterase activity 
may therefore te used as a test of liver function or as an 
index of protein synthesis. 
Many forms of liver disease including cirrhosis [La Motta, 
Williams and wetstone 19571, chronic hepatitis (Singh et 
al. 19761 and malignant disease with secondary liver 
deposits (Ghooi, Malaviya and Kashyap 19801 have been 
shown to be accompanied by reduced enzyme activity. There 
is always reduction of esterase levels following 
starvation and in particular kwashiorkor [Srikantia, Jacob 
and Reddy 19641. Cholinesterase activity is low in other 
pathological conditions including chronic renal disease 
[Simon et al. 19691, myocardial infarction (Chawhan et 
al. 1982], burns [Viby-Mogensen et al, 19751, anaemias 
(Vorhaus and Kark 1957], myxoedema (Thompson and Whittaker 
19651, tuberculosis C Vaccarezza, Wilson and Bochi 19661, 
Crohns disease [Sategna-Guidetta, Bianco and Durazzo 19801 
and cancer [Kanaris et al. 1979). It is probable that this 
is due to a secondary reduction in protein synthesis. 
However it is also possible that enzyme synthesis is 
reduced as a result of derangement of the metabolic 
processes of the hepatocyte by materials produced in the 
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diseased tissues or that enzyme activity is inhibited by 
toxic materials. The reduction seen in cancer is greater 
than that of albumin or total protein and has led to the 
suggestion that there is a humoral effect of cancer cells 
on cholinesterase production or activity (McComb, LaMotta 
and Wetstone 1964). 
There have been many reports of alterations in 
cholinesterase gene frequency with disease. The majority 
of these have involved the observation of an increased 
incidence of the fluoride resistant gene. Whittaker, 
Spencer and Searle (19771 noted three of four patients, 
_ 
who had survived malignant h1perpyrexia who were 
heterozygous for the usual and fluoride resistant gene and 
that this gene was functioning in two additional families 
who had lost blood relatives as a consequence of the 
disease. This finding was supported by Ellis and 
colleagues [19781 but not by other workers [Evans et al. 
1981]. An increased incidence of the El 
f 
gene has also 
been reported in patients with Down's Syndrome [Drew and 
Rundle 19771, mental illness (psychosis and Huntingdon's 
chorea) [Whittaker and Berry, 19771 and in patients 
undergoing lithium therapy [Whittaker and Spencer 19771. 
Studies on gene frequencies in leprosy have also yielded 
conflicting results some workers finding a high incidence 
of the atypical gene [Navarrete, Lisker and Perez-Briceno 
19791 and others not [Rea and Ng 19781. Such controversy 
highlights the difficulties of precise cholinesterase 
28 
phenotyping and especially in the identification of the 
fluoride resistant gene. Fluoride inhibition of 
cholinesterase is not straightforward (Heilbron 1965] and 
probably involves prior formation of a fluorophosphate 
complex which acts as the actual inhibitory agent. In 
addition it is a difficult inhibitor to handle in the 
laboratory. Some workers have suggested using only freshly 
prepared stock solution or adding the inhibitor 
i, -m-diately before analysis. Even so the degree of 
inhibition of the hydrolysis of benzoylcholine appears to 
fall during the. reaction and consequently it has been 
advocated that measurerents be taken only during the first 
5-7 minutes of the assay [Evans 19861. 
In routine clinical chemistry the measurement of 
cholinesterase has been most widely used in the 
investigation of liver disease. In the early stages of 
acute hepatitis the plasma enzyme level is slightly 
reduced but a substantial fall indicates the development 
of complications. In both chronic hepatitis and cirrhosis 
low to normal cholinesterase activities are found. 
Generally there is good correlation between the functional 
state of the liver and cholinesterase activity. A sudden 
fall- in, activity may indicate developing hepatic failure 
but if acute illness is sufficiently -severet .. death may 
occur before any change in cholinesterase is seen. This is 
probably due to the short half life of Ithe -enzyme,, 
estimated between 3.4 and 16 days [Brown et al. 19811. - 
Cholinesterase is used as a routine liver function test in 
29 
many countries of Europe but not the United Kingdom. The 
wide range of cholinesterase values seen in the healthy 
population makesý the interpretation of isolated values 
seen ý'during an illness difficult. Interpretation is- 
further hindered by the occurrence of the genetically 
determined abnormalities which give rise to reduced 
cholinesterase-levels unassociated with disease., Evidence 
has also been presented which suggests that cholinesterase 
measurements do not contribute significantly more to the 
diagnosis and management of liver disease than other tests 
of liver function, (Gross, - Audetat-and -Bircher 19781. 
However cholinesterase measurements have been-found useful 
when -dealing with specific liver problems such as ý the 
surgical treatment of the cirrhotic patient [Hunt and 
Lehmann 19601 and the monitoring of liver transplants 
(Evans and Lehmann 19711. 
In other disease states the measurement of cholinesterase 
is of little importance unlessý administration of 
succinylcholine is considered. Even then reductions in 
enzyme activity are rarely sufficient to put patients at 
risk of sensitivity to the drug. 
5.2 Tn toxicology: 
Irreversible inhibition of plasma cholinesterase occurs as 
a consequence of poisoning with anticholinesterase 
insecticides, principally carbamates and organophosphates. 
These conpounds -are extremely toxic , and their 
characteristic effects ' are due to inhibition of 
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acety1cholinesterase at the neuromuscular junction. Both 
erythrocyte acety1cholinesterase and serum cholinesterase 
can be estimated as indices of poisoning. When exposure 
ceases cholinesterase activity returns to normal after 
five to six weeks as the enzyme is resynthesised by, the 
liver. It takes approximately four months for the red 
cells to be replaced and acety1cholinesterase activity to 
achieve normal levels. , The measurement of serum 
cholinesterase is preferred -for the screening and 
monitoring of this type of insecticide poisoning as it is 
easier to determine accurately, and precisely. However it's 
use in this situation is not without problems, especially 
if - baseline activities for comparison are unavailable. The 
wide range of cholinesterase levels seen withiný, the 
populac-on make it difficult to be sure whether poisoning 
has, occurred, particularly if the level of intoxication is 
low. On those occasions when , cholinesterase is 
congenitally lowered or absent acety1cholinesterase will 
need to be measured as an index of poisoning. 
5.3 In succinylcholine apnoea: 
Succiny1choline, a depolarising neuromuscular blocking 
agent, was first introduced into clinical practice in 1951 
and is now widely used, facilitating such procedures as 
intubation and electric convulsive therapy (ECr). Wen the 
drug is injected intravenously in the usual dosage, 
1mg/kg, most is hydrolysed by plasma cholinesterase within 
the first minute [Kalaw 1962]. A small fraction of the 
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drug Feaches the post-junctional membrane at the 
neuromuscular junction and competes with acetylcholine for 
cholinergic receptors. It produces an acetylcholine like 
but prolonged depolarisation of the end-plate. This 
depolarisation. spreads to the surrounding, muscle fibres 
making them unexcitable. The duration of action of the 
drug is approximately 2-5 minutes. During this time, after 
an initial contraction, the muscle fibres passively 
elongate to give the relaxation required by the 
ar. aesthetist. All the skeletal muscles including the 
respiratory muscles are affected. Prolonged paralysis 
occurs whenever the breakdown of succiny1choline is 
reduced. This sensitivity to succiny1choline may arise in 
several situations; pregnancy (Evans and Wroe 19801 
especially when coupled with plasmapheresis -for rhesus 
haemolytic disease [Evans, Macdonald and Robinson 19801, 
liver disease (Singh et al. 19761, certain disease states 
especially chronic debilitating diseases, poisoning from 
organophosphorus insecticides (Mackey 19821, . 
and in 
patients with genetically determined enzyme abnormalities 
(Viby-Mogensen 19831. In all affected 
'patients 
the 
inability to use the muscles of the chest in order to 
hreathe requires them to be artificially ventilated until 
the succiny1choline is. eliminated, either by spontaneous 
, 
hydrolysis or excretion through the kidney. 
Apnoea is most prolonged in patients with genetically 
determined abnormalities of cholinesterase when it may 
32 
last for several hours [Viby-Mogensen 19831. Goedder, Held 
and Atland (19681 demonstrated that the atypical enzyme 
has a much lower affinity for succinylcholine and 
succinylmonocholine than the usual enzyme and thus is 
unable to hydrolyse the drug at pharmacological 
concentrations. This was later confirmed by Hobbiger and 
Peck [19711. Altered affinity has not been shown for other 
enzyme variants but this is. likely to tolbe the case. The 
aaafas genotypes most susceptible are El El , El El I El El 
fffss El El I El Els and El El . In general individuals who are 
heterozygotes for the usual enzyme are not sensitive to 
succiny1choline in the absence of complicating, factors. 
In cases of succiny1choline sensitivity where the enzyme 
is not abnormal apnoea is not so prolonged (Anon. 19731. 
Viby-Mogensen [19801, in a study correllating the duration 
of action of succinylcholine with plasma cholinesterase 
activity in subjects with phenotypically usual enzyme, 
demonstrated that even cholinesterase activities 30% of 
the 
-lower, 
limit of normal resulted in an apnoea of only 
approximately 20 minutes. He suggested that the prolonged 
apnoeas seen in similar patients, [Hunter 1966] were due to 
factors other than low plasma cholinesterase activity. 
Additional reasons- for the prolonged apnoea, have been 
postulated. 
a) Enzyme inhibition [Anon. 19731 






and Sigiel 1976). 
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c) A change 'in the character of the succiny1choline 
block [Lee 19751. 
d) Abnormalities in the response of the muscle end plate 
[Brown et al. 19811. 
e) Other factors such as hyperventilation and/or residual 
narcotic effect [Viby-Mogensen 1980). '' 
Nonetheless from a practical point of view when enzyme 
activities fall 2.5 SD below the mean for Elu homozygotes 
there is a greatly increased risk of some degree of 
sensitivity. 
In all analyses of patients presenting with prolonged 
apnoea following succiny1choline administration there is a 
high incidence of patients (28-50%) where both genotype 
and plasma cholinesterase activity are normal (Kalow 1965, 
Lehmann and Liddell 1969, Whittaker and Vickers 1970, 
Bauld et al. 1974, and Viby-Mogensen and Hanel 1978]. 
Bauld et al. (1974] first postulated that this might be 
due to the existence of abnormal genotypes not 
demonstrable by the biochemical methods at present 
employed. variants of cholinesterase might exist which 
whilst able to hydrolyse substrates used in their assay 
cannot hydrolyse succinylcholine. To explore such a 
possibility succiny1choline should be used as the 
substrate for the measurement of plasma cholinesterase. 
Bauld and coworkers pointed out some of the problems this 
would entail and advocated the use of 
succiny1dithiocholine, a close analogue. Agarwal et al. 
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[19751 developed an assay based upon succinylcholine and 
using this method Goedde and Agarwal (19781 claimed they 
were able to explain up to 90% of previously unexplained 
cases of abnormal reaction to succinylcholine. They 
maintained that there was a further gene El su detectable 
only using this substrate. This work has not yet been 
substantiated. 
1.6 CHOLINESTERASE IN ANIMALS. 
Cholinesterase was first recognised in horse serum 
(Stedman, Stedman and Easson 19321 and has since been 
found to occur widely in the animal kingdom. Its 
distribution is diverse being found in mammals, reptiles 
(Lam 19771, birds [Earl and Thompson 19521, fish and 
amphibians [Augustinsson 19591. 
Specificity of cholinesterase towards choline and non- 
choline esters, sensitivity to inhibitors, activity- 
substrate concentration relationships and electophoretic 
patterns are all species dependant (Augustinsson 1948 and 
Augustinsson 1959a, b, cl. The source of the enzyme must 
therefore be stated in any work with cholinesterase since 
it is not possible to apply results' obtained with 
specimens from one species to that of another. 
Plasma from rats, rabbits, chickens and frogs have 
propionylcholinesterases, that is have maximum activity 
when cholinesterase is measured using a 
propionylthiocholine substrate. Their properties- however 
are different with respect to inhibitor-sensitivity, 
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kinetic and electrophoretic behaviour. In contrast plasma 
specimens from higher order vertebratest mant horses and 
dogs; contains cholinesterase with a maximum activity 
against butyrylthiocholine. The enzymes show similar 
biochemical properties bu t have different molecular form 
as shown by electropýh6resis. Augustinsson [1959c and 19681 
further considered the evolutionary implications of the 
patterns of substrate specificity. He proposed that 
cholinesterases and carboxylesterases had evolved from a 
coumn "serine enzyme" precursor. He suggested that during 
evolution cholinesterases acquired an anionic site which 
conferred a special ability to bind cationic substrates. 
Further mutational changes resulted in the development of 
differing specificity, butyry1cholinesterases evolving 
from the propionyl- type. 
Although cholinesterase is present throughout the animal 
kingdom and, according to Augustinsson's theory, actively 
retained as part of an evolutionary process separate from 
acetylcholinesterase, it's function and natural substrates 
are not known. Nonetheless the measurement of animal 
cholinesterase does have some practical importance. It is 
of value in determining the degree of exposure of animals 
to anticholinesterase compounds (Silvestri 1977' and 
Crookshank and Palmer 19781 and has been used to provide 
information concerning the pharmacological effect of 
succiny1choline in different species [Wright et al. 19811. 
Succinylcholine was first used as a muscle relaxant in 
veterinary practice in the early 1950's. It has also been 
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used for the translocation or culling of wild animals 
when, depending on the dose, it acts either to immobilise 
or to cause death by paralysis of the respiratory muscles 
(Berger et al. 1983, Wright et al. 19811. considerable 
controversy surrounds such use since drug action occurs 
with complete retention of conciousness which aggravates 
the state of anxiety of the animals. Continued use of the 
drug in these situations cannot be condoned with the 
advent of powerful cpioid sedative drugs which can be 
reversed, if necessary, by specific antagonists (weaver, 
Dept. of Veterinary medicine, Bristol University, personal 
comunication]. However despite this, use of 
succinylcholine has been advocated in translocation of 
horses in preference to other drugs [Berger et al. 19831 
and it is still used in culling operations 'for want of a 
tetter method" (Anon. 1984]. In veterinary medicine the 
drug is reserved for intubation of cats and for use in 
horses as an adjunct to thiopentone, so that if 
thiopentone- has been slightly underdosed the handlers of 
the horse are not injured by any subsequent excitement 
reaction. 
A problem complicating the use of succiny1choline is the 
wide species variation in sensitivity. Hansson [19571 
showed considerable differences in sensitivity in four 
domestic animal species and 'others demonstrated that 
these also exist in the wild [Buecher, Harthoorn and Lock 
19601. 
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Viby-Mogensen 1980 showed that plasm 'cholinesterase 
activity, in man, was related to the effect of 
succiny1choline and he was able to predict the duration of 
apnoea following a single dose of the drug. - It seems 
likely therefore'that cholinesterase activity may provide 
a guide to the susceptibility of different species to 
succinylcholine. This is important for the assessrent of 
effective dose levels. Wright et al. [1981] investigated 
26 species but concluded that plasma cholinesterase 
activity was unlikely to give more than- a very 
approxim, te guide to their susceptibility to paralysis by 
the drug. However the substrate which he used - for 
measuring cholinesterase activity was tutyrylthiocholine. 
It may be that the ability of animal plasma to hydrolyse 
butyrylthiocholine in vitro is not directly related to 
the ability to hydrolyse and thus, terminate the action of 
succiny1choline in vivo. A more appropriate assay system 
would be one lased upon succinylcholine. 
1.7 MEASUREMERr OF PLASMA 
Many techniques have been described f or the measurement of 
plasma cholinesterase ranging -from simple colorinetric 
procedures to assays which rely on the gas chromatographic 
detection of reaction products [Somorin 19781 or the use 
of a radiolabelled substrate [Hoover et al. 19761. However 
few are amenable to routine use. methods which have been 
used routinely can be divided into three groups. 
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a) Those which measure the liberation of acid from a 
cholinester. 
Acid formation has been monitored as follows: 
i) by measuring the carbon dioxide released from a 
bicarbonate-containing medium in the Warburg manometric 
apparatus [McArdle 19401. 
ii) by the time taken to achieve a fixed pH 
electrometrically (Michel 19491 or colorimetrically 
using indicators such as phenol red (Reinhold, Tourigny 
and Yonan 19531 or bromothymol blue (Biggs Carey and 
Morrison 19581.. 
iii) by measuring the rate of titration required to 
maintain a constant pH (Alles and Hawes 19401. 
iv) by monitoring the change in pH in the Astrup micro 
equipment (Johnson and Whitehead 19651. 
b) Those which make use of chromogenic substrates. 
Hydrolysis of such substrates by cholinesterase 
produces a compound which is coupled with an indicator 
to yield a product which can be measured 
colorimetrically. 
The most widely used assays of this type are those in 
which a sulphydryl group is released from a thiocholine 
ester. This can be followed by using the nitroprusside 
colour reaction [Mcosker and Daniel 19591, by 
iodometric titration [Augustinsson 19551, by coupling 
to the reduction of 2: 6 dichlorophenolindophenol (Gal 
and Roth 19571, by complexing with 2j2' or 4,4'- 
dithiodipyridine [Uete et al. 19721 or with dithiobis- 
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(2-nitrobenzoic acid) [Ellman et al. 19611. 
c) Those in which the unreacted ester is measured. 
This has been done in f ixed-tirre assays using an 
acetylcholine substrate by means of the ferric- 
hydroxamate reaction (De La Huerga, Yesinick and Popper 
1952] or with benzoylcholine by following the decrease 
in absorbance at 240 nm [Kalow and Lindsay 19551. This 
last assay is probably the most widely used of all 
cholinesterase assays since the routine ascription of 
cholinesterase genotype relies predominantly on the 
inhibition of benzoylcholine hydrolysis. 
Sutstrates which are the most widely used at present for 
measurement of cholinesterase activity are those amenable 
to Uv/visible spectrophotometry. They include 
benzoylcholine and the thiocholine esters. In most 
laboratories the benzoylcholine assay is used to establish 
cholinesterase genotype and therefore, if used for 
activity measurements, has the advantage that results can 
be obtained simultaneously * It is also specific. It 
,s 
disadvantages are that the X max for benzoylcholine is 235 
run a wavelength at which protein absorbs strongly. Because 
of this problem the reaction is monitored at 240 ro, a 
wavelength not optimal for the substrate and at which some 
protein absorbance still occurs. Furthermore the optical 
density change is small which increases analytical 
imprecision. 
Assays using thiocholine esters as substrates are very 
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sensitive and so measurements may be made using small 
volumes of plasma. The first assay of this type used 
acetylthiocholine as the substrate but was established to 
measure cholinesterase in tissue extracts and cell 
suspensions (Ellman et al. 19611. It was later applied to 
blood by Garry and Fouth (19611. Disadvantages arise from 
the instability of acetylthiocholine in solution and it's 
nonspecificity. It is susceptible to hydrolysis by 
acety1cholinesterase and therefore if applied to plasma 
care must be taken to avoid even the slightest haemolysis. 
These problems have been overcome by the use of other 
thiocholinesters, notably butyrylthiocholine (Das and 
Liddell 19701 and propionylthiocholine [Dietz, Rubinstein 
and Lubrano 19731. Both these substrates are more stable 
than acetylthiocholine in solution, are more specific to 
cholinesterase and are more rapidly hydrolised. Both have 
been recommended as the substrate of choice for the 
measurement of plasma cholinesterase [Silk, King and 
Whittaker 1979 and Dietz# Rubinstein and Lubrano 19731. 
The choice of technique for the measurement of 
cholinesterase activity, like any other parameter in 
clinical chemistry,, depends upon many factors including 
speed and ease of assay# precision, accuracy and cost. 
However the main factor which should govern the choice of 
any assay procedure and particularly an enzyme, should be 
it's ability to answer the clinical question. The main 
clinical requirement for measurements of cholinesterase 
activity concerns the investigation of suspected 
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succinylcholine sensitivity. Only to a lesser extent is it 
used as a liver function test or in the investigation of 
poisoning by organophosphates and related compounds. 
The recommendation that butyrylthiocholine be the 
substrate of choice for the measurement of plasma 
cholinesterase [Silk, King and Whittaker 19791 did not 
take into consideration it's ability to provide useful 
clinical information. A study by Evans and Wroe (19791 
assessed this. They investigated a large group of 
patients, defined as being sensitive to succinylcholine 
or not according'to clinical criteria or cholinesterase 
genotype. Cholinesterase activity was measured using 
benzoylcholinet acetylcholine, butyrylthiocholine and 
propionylthiocholine as the substrates. It was shown that, 
on the basis of enzyme activity alone, whilst 
benzoylcholine identified only 50% of affected patients, 
propionylthiocholine increased this to over 90%. 
Acetylcholine and butyrylthiocholine gave intermediate 
figures [Evans and Wroe 1979]. The authors therefore 
advocated the use of propionylthiocholine for the 
measurement of cholinesterase arguing that it was the 
substrate that maximised clinically useful information. 
Despite this propionylthiocholine only identified 91-96% 
of sensitive patients, depending on the cut-off value 
chosen. In theory an assay using a succinylcholine 
substrate should enable the identification of an increased 
proportion of sensitive patients since there may be, as 
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postulated by Bauld et al. [19711, enzyme variants which 
hydrolyse non-pharnacological substrates but not 
succinylcholine. Succinylcholine-based assays have been 
described but since neither the drug itself nor it's 
hydrolysis products have, until recently, been amenable 
to spectrophotometric analysis such methods have not been 
suitable for routine use. Previously described techniques 
have involved: 
a) Electrophoretic . separation of 
14 c labeiled 
succiny1choline from its products of hydrolysis by 
cholinesterase [Schmidinger, Held and Goedde 19661 and 
a similar technique using thin layer chromatographic 
separation [Agarwal and Goedde 19761. 
b) Monitoring the rate of fall of pH, resulting from the 
release of the carboxyl group from succinylcholine, in 
the Astrup micro pH apparatus (Fishtal, Evans and 
Chapman 19721. 
c) The use of a bioassay technique for the detection of 
unchanged succinylcholine (Hobbiger and Peck 19691. d) 
The use of choline oxidase (EC 1.1.3.17) to measure the 
choline released after hydrolysis of succinylcholine by 
cholinesterase (Agarwal et al. 19751. In this procedure 
choline oxidase was used to convert choline to betaine 
aldehyde. This reaction was followed by coupling it to 
the reduction of cytochrome c which can be monitored at 
550 nm. A rat liver mitochondrial preparation was used 
as the source of the choline oxidase. 
The recent commercial availability of choline oxidase has, 
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for the first time, given rise to the prospect of 
developing a ýsinple analytical procedure for a 
succiny1choline-based ýcholinesterase assay which can te 
. applied to the routine identification of succiny1choline 
sensitive individuals. ý, 
1.8 ADIS 
1. To develop an assay for plasma 1, cholinesterase using 
succinylc I holine as the substrate'which is -applicable to 
use in routine clinical chemistry laboratories. 
2. To evaluate the ability of the assay to def ine 
individuals at risk of sensitivity to succinylcholine and 
corpare it to a propionylthiocholine-based assay, 
previously shown to be the best available for this 
purpose. 
3. To establish whether there exist abnormal forms of 
cholinesterase which can hydrolyse conventional assay 
substrates but not succiny1choline. 
4. To investigate the kinetics of the succinylcholine- 
cholinesterase reaction using the newly described assay. 
5. To evaluate the usefulness of the succinylcholine-based 
assay in the assessment of liver dysfunction and compare 
it to established cholinesterase assays. 
6. To use the succinylcholine-based assay to investigate 
whether the increased dose of succiny1choline required to 
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muscle 'relax-neonates and infants compared to adults is 
due to a difference in the ability of their respective 
cholinesterases to hydrolysethe drug. 
7. To apply the succiny1choline-based assay and three 
conventional assays to a variety of animal species to 
i) document differences in their ability to hydrolyse 
a range of substrates. 
ii) to establish whether they can be used to predict 
species sensitivity to succiny1choline. 
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CHAMR 2: 
MAMRIAIS AND METEODS. 
2.1. MATERIALS: 
Adenosine tri-phosphate (ATP) 
Amicon Centriflo merrbrane 











Cholinesterase (purified huwan) 
Boehringer Corp. 
(London) Ltd., 
Lewes, U. K., 
Amicon Corporation 
Lexington, Mass., 
U. S. A. 
, B. D. H Chemicals Ltd., Poole, U. K. 
B. D. H Chemicals Ltd., 
Poole, U. K. 
Boehringer Corp., 
(London) Ltd., 
Lewes, U. K. 
Sigma Chemical Co., 
Poole, U. K. 
Sigma Chemical Co., 
Poole, U. K. 
Sigma, Chemical Go., 
Poole, U. K. 
Sigma, Chemical Co., 
Poolel U. K. 
Boehringer Corp., 
(London) Ltd., 
Lewes, U. K. 
Boehriner Corp., 
(London Ltd., 
Lewes, U. K. 
and 
Sigma Chemical Co., 
Poole, U. K., 
Sigma Chemical Co., 




Hoechst Pharma AG, 
Zurich, Switzerland. 
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Dibucaine hydrochloride Ciba Laboratories, 
Horsham, 
West Sussex. 
DiMethylsulphoxide (DMSO) B. D. H Chemicals Ltd., 
Poole, U. K. 
Disodium hydrogen phosphate Sigma Chemical Co., 
Poole, U. K. 
5,5'-dithiobis- Sigma Chemical Co.,. 
(2-nitrobenzoic acid) DTNB Poole, U. K. 
Intralipid Kabivitrum U. K. Ltd., 
Uxbridgel Middlesex. 
Lactate dehydrogenase Sigma Chemical Co., 
Poole,, U. K. - 
Peroxidase Hughes and Hughes, 
Romford, U. K. 
Phenol B. D. H Chemicals Ltd., 
Poole, U. K. 
Potassium dihydrogen phosphate Sigma Chemical Co.,, 
Poole, U. K. 
Propionylthiocholine iodide Sigma Chemical Co., 
Poole, U. K. 
Pyruvate kinase Boehringer Corp. 
(London) Ltd., 
Lewes, U. K. 
Qualify II, Freeze dried American monitor 
control material. U. K. Ltd., 
Burgess Hill, 
West Sussex. 
Ro 02-0683 dimethylcarbamate of Roche Pharmaceuticals 
(2-hydroxy-5-phenylbenzyl) Ltd.,, Welwyn Garden 
trimethylammonium bromide City, U. K. 
Sodium fluoride Sigma Chemical Co., 
Poole, U. K. 
Succinylcholine chloride Sigma Chemical Co., 
Poole, U. K. 
IYis Etris-(hydroxymethyl) Sigma chemical Co., 
-aminomethane]HCL Poole# U. K. 
Triton X-100 B. D. H chemicals Ltd., 
Poole, U. K. 
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2.2 ANALYTICAL MEMODS: 
2.2.1 MEASCREMIENr OF ENZYME ACrIVITY. 
All measurements of enzyme activity were performed using 
either a Pye Unicam, SP1800 spectrophotometer or on a Pye 
Unicam PU8800 UV/VIS spectrophotometer incorporating a BBC 
microcomputer (Pye Unicam. Instruments Ltd., Cambridge,, 
U. K. )ý 
a) Cholinesterase activity measured using benzoylcholine 
as the 3ubstrate. 
This assay ý was performed as described by Kalow and 
Lindsay (19551. It is a reaction rate assay in which 
cholinesterase activity is calculated by monitoring -the 
decrease in absorbance of unreacted benzoylcholine at 240 
nm. At this wavelength benzoylcholine has a much greater 
absorbance than it's products of hydrolysis, benzoic acid 
and choline. 
i) Reagents: 
Phosphate buffer: 0.067 mol/L, pH 7.4.47.98g Na 2 HPO 4' 2H29 
and 8.665g KH 2 PO 4 in five litres of water. 
Substrate: Benzoylcholine iodide. 
Stock solution: 2x 0 -3 mol L. 48.75mg in 100ML phosphate 
buffer. The solution was stored at 40c for a maximum of 
7 days. 
Working solution: 2x, 0-4 mo,, L. Stock solution was diluted 
1 in 10 in phosphate buffer and prepared freshly. 
ii) Procedure: 
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Serum was diluted 1 in 100 in phosphate buffer. 2mL was 
added to lmL phosphate buffer and lmL substrate. The 
reaction 
'was 
mI onitored at 240 nm and 250C against a blank 
solution with substrate replaced by buffer. 
Enzyme activity (IU/irL) is calculated by multiplying the 
change in absorbance per minute by 30.3. 
Precision was assessed using Qualify II,, a commercially 
prepared freeze-dried quality control material. The assay 
had a tetween batch coefficient of variation of 6.4% 
(n=12), at 0.45 IU/mL. 
(ii) Cholinesterase activity measured using 
butyrylthiocholine as the substrate: 
The meth6d of Das and Liddell [1970blwas used in which 
cholinesterase' hydrolyses butyrylthiocholine 'to give 
butyric acid and thiocholine, the free sulphydryl of which 
reacts with 5,5' -dithiobis-(2--nitrobenzoic acid)(DTNB). 
This yields the 5-thio-2-nitrobenzoate ion which has an 
absorbance maximum at 410 nm. DTNB absorbs maximally at 
320nm. 
i) Reagents: 
Phosphate buffer: 0.067 mol/L., pH 7.4.47.98g Na 2 HP04 *2H 20 
and 8.665g KH 2PO4 in 5L of water. 
Substrate: Butyrylthiocholine iodide 225 mmol/L. 
7.137g in 100mL phosphate buffer. 
DTNB: 0.27 mmol/L. 
214mg in 2L phosphate buffer. The solution was stored at 
40C in a dark glass bottle. 
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ii) Procedure: 
10 or 20 ul plasm and 100 uL butyrylthiocholine iodide 
were added to 2.9 mL aliquots of DTNB, mixed and the 
reaction monitored at 408 nm and 25 0C against a blank 
solution in which the serum had been replaced by buffer. 
Enzyme activity (IU/mL) was calculated by multiplying the 
change in absorbance per minute by 221/uL of sample. 
A commercially prepared freeze-dried quality control 
material, Qualify II, was used to assess precision. The 
assay had a between batch coefficient of variation 5.1% 
(n=12), at 2.67 IU/mL. 
(iii) Cholinesterase activity measured using 
propianylthiocholine as substrate: 
The assay principle is the same as described for 
butyrylthiocholine. The method of Dietz, Rubinstein and 
Lubrano, [19731 was used. However two modifications were 
made as their assay showed an inconveniently high 
sensitivity. The temperature was reduced to 25 0C and the 
volume of diluted serum also reduced, from 1000 to 500 U. 
The final volume, 5 ML, was achieved by increasing the 
volume of DTNB solution from 3 to 3.5 mL. These 
modifications diminished the rate of increase in 
absorbance for Elu homozygotes from a mean value of 0.25 
units per minute to 0.07 units per minute. This enabled 10 
measurements to be made at 1-minute intervals, thus 
increasing the accuracy of calculation of the rate of 
absorbance change without exceeding the capacity of the 
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spectrophotometer (Evans and Wroe 19781. 
Reagents: 
Phosphate buffer: pH 7.6. 
Separate solutions of 13.61g KH 2 PO 4 per litre and 7.413g 
Na 2 HPO V 2H2 0 per litre were mixed to give a final pH of 
7.6. 
DTNB: 0.423 mmol/L. 
334mg in 2L of phosphate buffer. This*was stored at 40C in 
a dark glass bottle. 
Substrate: Propionylthiocholine iodide Mmnol/L. 
6.064g in 1L phosphate buffer. This was stored at -200C in 
aliquots of various volumes and thawed as required. 
ii) Procedure: 
Serum was diluted 1 in 100 in phosphate buffer. 0.5mL was 
added to 3.5irL DTNB and mixed. lmL substrate was added, 
the reagents mixed again and the reaction monitored at 
0 408nm and 25 C against a blank solution in which diluted 
serum was replaced by buffer. 
Enzyme activity (IU/mL) was calculated by multiplying the 
optical density change per minute by 73.67. 
Precision was assessed using Qualify if, a freeze-dried 
quality control material. - 
The assay had a precision of 3.0% (n--12), at 2.82 IU/mL. 
2.2.2'AKRIPTION OF CM laß'TERASE GENMIYPE. 
This was made on the basis of inhibition of benzoylcholine 
hydrolysis by dibucaine [Kalow and Genest 195711 fluoride 
[Harris and Whittaker 19611 and the dimethy1carbamate of 
51 
(2-hydroxy-5-phenylbenzyl) trimethylammonium bromide (Ro 
02-0683) [Liddell, Newman and Brown 1963] and where 
possible, family studies. 
D Reaqents 
Phosphate buffer: 0.067 mmol/L pH 7.4. 
47.98g Na 2 HPO 4* 2H20 and 8.665g KH 2PO4 in 5L of water. 
Substrate: Benzoylcholine iodide. 
Stock solution: 2xl 0-3 mol/L. 48.75mg in 100mL phosphate 
buffer. This was stored at 40C for a maximum of 7 days. 
Working solution: 2x 10-4 mol/L. Stock solution was diluted 
1 in 10 with phosphate buffer and prepared freshly. 
Inhibitors 
Dibucaine hydrochloride. 
Stock solution: 4x, 0-4 mol/L. 
15.2mg in lOOrnL phosphate buffer. This was stored frozen 
in 10-20mL aliquots and thawed as required. - 
Working solution: 4xlO- 
5 
mol/L. 
Stock was diluted 1 in 10 with phosphate buffer and 
prepared freshly on day of test. 
Ro 02-0683. 
Stock solution: lxlO- 
4 
mol/L and lxlO- 
6 
mol/L. 
39.6mg in 1L phosphate buffer and 1 in 100 dilution with 
phosphate buffer. These were stored at 40C at which 
tent>erature they are stable indefinitely. 
Working solution: U10-8 mol/L. 
4mL lxlO- 6 mol/L is made up to 100irL with phosphate buffer 
and stored at 40C. 
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Sodium fluoride 
Stock solution: 2x, 0-3 mol/L. 
84mg in 1L phosphate buffer. This was stored at room 
terperature. 
Working solution: 2xlO- 
4 
mol/L. A1 in 10 dilution of 
stock in buffer was made on the day of test. 
b) Procedure: 
Serum was diluted 1 in 100 using phosphate buffer. 2 mL 
was added to each of 4 tubes. lmL buffer was added to tube 
1 and lmL of an inhibitor added to the remainder. 
Inhibition of enzyme activity by Ro 02-0683 requires a 
minimum of two hours preincubation at room temperature 
before the addition of lmL-of substrate. Fluoride and 
dibucaine are added prior to the addition of 'substrate. 
Ilie reaction was' monitored at 260C and 240nm. ' The 
inhibitor numbers (percentage inhibition of benzoylcholine 
activity by each'of the inhibitors) were calculated as 
follows: 
Inhibitor Nurber, = 100(v-v* 
v 
where v is the uninhibited velocity and v' is the 
velocity in the presence of inhibitor. 
2.2.3 PREPARATION OF ICTERIC SERA. 
7he nethod of Billing, Haslam and Wald [1971] was used. 
a) Reagents: 
Dimethylsulphoxide (DMSO). 
Bilirubin: 98 mg in 20 mL dirmthylsulphoxide. 
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Serum: A serum pool was made by mixing the residue of 
samples sent to the laboratory for routine investigations. 
b) Procedure: 
Bilirubin was dissolved in DMSO. Warming at 370C for 1 
hour ensured complete solution. 400,200 and 100 UL 
aliquots of the bilirubin solution were each made up to 10 
mL with serum to give samples with approximate bilirubin 
values of 340,170 and 85 umol/L respectively. Assayed 
values were 365,195 and 105 umol/L respectively measured 
on a Unistat bilirubinometer (A. 0 Scientific Instruments). 
The higher observed values were due to the bilirubin 
present in the pooled sera used to make the dilutions. 
2.2.4 uLTRAFILTRATiON op sEpum. 
Amicon Centriflo membrane cones of type CF25 were used for 
ultrafiltration. Before ýuse the, cones were soaked in 
distilled water for at, least one hour then blotted and 
centrifuged to remove excess water. Serum was added to the 
cones and centrifuged at 850 g ýfor 20 minutes. This 
concentrated high molecular weight molecules by the 
removal of an ultrafiltrate consisting of serum water and 
dissolved crystalloids. 
2.2.5 LIVER FUNCTION TESTS. 
These were performed on automated - equipment either an 
RA1000 analyser (Technicon. Ltd., Basingstoke) in the 
Department of Chemical Pathology, Leeds General Infirmary 
or -on a Parallel analyser (American monitor U. K. Ltd. j, 
Burgess Hill,, - West Sussex) in the Department of -Chemical, 
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Pathology, St. James's University Hospital, Leeds. 
a) RA1000: 
Bilirubin, aspartate transaminase (EC 2.6.1.1) and 
alkaline phosphatase -(EC, 3.1.3.1) were measured using 
manufacturers reagents, by assays based on the following 
methods, bilirubin [Jendrassik and Grof 19381, aspartate 
transaminase (Kessler et al. 1971] and alkaline 
phosphatase [Besseyo, Lowry and Brock 19571. 
b) Parallel: 
Total protein, albumin, bilirubin, alanine transaminase 
and alkaline phosphatase were measured using manufacturers 
reagents assays based on the following methods, total 
protein by a method employing the biuret reaction, albumin 
by a dye binding assay using bromocresol green [Rodkey 
1965], bilirubin by a method based on that of Jendrassik 
and Grof [19381, alanine transaminase (EC 2'. 6.1.2) 
(Karmen, Wroblewski and La Due 19551 and alkaline 
phosphatase (Bowers and McComb 19751. 
2.3 STUISTIChL METHODS. 
Statistical analyses were performed on either a Digico 
Consort 20 Computer (Digico Ltd., Hemel Hempstead, U. K. ) 
using "in-houseO software (St. Jams's University 
Hospital) or on an Amstrad PC1512 conputer (Amatrad 
Electronics p1c, Brentwood, U. K. ) using Oxstat 2 (Medstat 
Ltd., Nottinghamp U. K. ). 
Enzyme kinetic data was analysed on a BBC Microcomputer 
(Acorn Computers, Cambridge, U. K. ] using a program 
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obtained from the Biochemistry Departmentr University of 
Leeds [England 19841. The program is based on one for non- 
line ar regression and allows data to be fitted to a series 
of I predefined equations representing, the more comnonly 
occuring mechanisms. The equation: 
v= Vmax /(l + Km/[SD 
representing Michaelis-Menten kinetics was used. 
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CHAPTER 3: 
THE DEVEU)PMERr OF A SUCCINYLCHDLINE-BASED ASSAY FCR 
SERUM CHOLINESTERASE. 
Assays for cholinesterase which use succiny1choline as a 
substrate have been described before. However,, because of 
their corplexity, none have easily been applied to routine 
use. I-I 
The aim of this section of the project was to develop a 
simple assay which could be used in any clinical chemistry 
laboratory. 
The approach taken was to base an assay on the measurement 
of the choline released followinq succinvlcholine 
hydrolysis. 
In 1975 Agarwal and coworkers described an assay for 
cholinesterase based on a succiny1choline substrate- in 
which the choline generated was measured enzymatically as 
follows: 
cholinesterase 
Succinyldicholine + H20 --+ succinylmonocholine + choline 
choline oxidase 
Choline 0 betaine aldehyde + 2H 
cytochrome C oxidase 
cytochrome C+ 2H 0 reduced cytochrome C 
A rat liver mitochondrial preparation was used as the 
source of choline oxidase (EC 1.1.3.17) and cytochrome C 
oxidase., Reduced cytochrome C was measured at 550 nm after 
the addition of potassium cyanide to prevent reoxidation. 
7here are two drawbacks to the routine use of such a 
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method; the extraction of rat'liver mitochondria and the 
use of toxic potassium cyanide. 
Two developments allowed me to overcome these drawbacks. 
a) The commercial availability of choline oxidase from 
Arthrobacter globiformis (Boehringer Corp. (London) Ltd., 
Lewes, U. K. ). -I 
b) The description of an alternative indicator reaction 
[Takayama et al. 1977]. In this reaction all. the reagents 
are in common use in clinical chemistry laboratories and 
are less toxic than potassium cyanide. 
The assay described by Takayama and coworkers measured 
phospholipids. Phospholipase D splits lecithin, 
lysolecithin and sphingomyelin to yield choline., Using 
choline oxidase this is converted to betaine with the 
simultaneous formation of hydrogen peroxide. Hydrogen 
peroxide, in the presence of peroxidase (EC 1.11.1.7), 
converts phenol and 4-aminophenazone to a red quinone dye 
in proportion to the amount of choline liberated. The 
change in optical density at 500 nm (absorbance maximum 
for the red quinone dye), following incubation at 37 0C for 
20 minutes, is compared to that of a standard lecithin 
solution and the phospholipid concentration calculated. 
TO produce a succinylcholine-based assay for 
cholinesterase it was necessary to replace the step 
involving the splitting of lecithin by one involving the 
hydrolysis of succiny1choline by cholinesterase. The basis 
of this assay is as follows: 
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cholinesterase 
Succinyldicholine +H2 0- succinylmonocholine + choline 
choline oxidase 
Choline + 02ý2H20 betaine +2H 202 
peroxidase 
2H 202 + phenol + 4-aminophenazonetquinone dye + 2H20 
3.1 Preliminary Investigations. 
In initial experiments concentrations of reagents were as 
recommended by Takayama and colleagues; 100 IU choline 
oxidase, 220 IU peroxidase, 12 mg 4-aminophenazone, 20 mg 
phenol and 8mg calcium chloride dihydrate in 100 mL 50 
rrol/L Tris/HCl buffer (pH 7.8 and containing 2g Triton 
X-100 per litre). Hereafter referred to as colour 
reagent. For the assay of cholinesterase it was necessary 
to reduce the pH of the solution to 7.4 to avoid 
spontaneous hydrolysis of succinylcholine. 
50 uL of 10 mmol/L succiny1choline and 50 uL of serum 
with high cholinesterase activity were incubated at 
370C with 3 mL of colour reagent. The reaction was 
monitored at 500 nm for 40 minutes against a colour 
reagent blank. The optical density change was linear over 
this period. As commercially prepared choline oxidase is 
expensive the colour reagent volume was reduced to 1 ML 
and the experiment, repeated. -The reaction remained 
linear. 
3.2 Determination of the most appropriate blank solýticn 
for use in the assay. 
a) Five different sera were each added to colour reagent 
59 
and monitored f or 10 minutes against colour reagent 
alone. -No optical density increase was observed using 
any of the sera and it was concluded that endogenous 
choline did not interfere with the assay. 
b) Colour reagent alone was observed against a water 
blank for 10 minutes and no optical density increase 
was observed. 
C) Four stock succinylcholine concentrations of 10,25, 
50 and 100 mmol/L (equivalent to *in assay" 
concentrations of 0.454,1.14,2.27 and 4.54 mmol/L 
repectively) were added to colour reagent and each 
measured f ive times against colour reagent alone over 
10 minutes. An increase in optical density was 
observed, proportional to the concentration of 
substrate. Results are shown in Fig. 3.1. 
It was concluded that a blank containing substrate would 
be essential to offset the non-enzymatic hydrolysis of 
succinylcholine. 
3.3 Investigation of linearity. 
A linear relationship between cholinesterase activity 
and reaction rate was established by assaying, the 
following sera undiluted and diluted in buffer to 
provide sample pools with 75, ' 50,25 and 10% of the 
original serum. 
a) a serum with an average cholinesterase activity., 
b) serum which had been concentrated by ultrafiltration 
using Amicon Membrane Cones. 
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Results are shown in Fig. 3.2. The assay is linear up 
to 145 IU/L ( r= 0.995). ,- 
3.4 Calibration. 
The assay was standardised using choline as the quantity 
of dye produced is stoichiometrically equivalent to the 
amount of choline oxidised. Three quantities of choline 
chloride 25f 50 and 100 nmoles were added to colour 
reagent, in quadruplicate, and the maximum amount of 
colour produced noted. Results are shown in Fig. 3.3. 
The relationship between choline added and final 
absorbance recorded is linear ( r= 0.9985). The y on x 
regression equation derived from the data is y= 0.0108x 
+ 0.0125. From this a factor can be derived to convert 
optical density change per minute to enzyme activity. 
Cholineiterase catalyses the hydrolysis of 
succinylcholine, as follows: - 
cholinesterase, 
1. Succiny1dicholine succiny1monocoline + choline 
cholinesterase 
2. Succiny1monocholine succinic acid + choline 
As reaction 2 proceeds much more slowly than reaction 1 
(Goedde, Held and Atland 1968], one mole of choline can 
te considered to-be- derived from one mole of 
succinylcholine. 
.1 unit of enzyme activity, 
is defined as the amount, 
which will catalyse the conversion of 1 -umole of 
substrate per minute. 
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The optical density change (J-\ OD) produced by loo 
moles choline is 1.09 absorbance units (AU). 
Therefore-the A OD produced by 1 umole choline is 10.9 
AU. 
However in the experiment 50 uL of choline - was 
substituted for 50 uL of substrate but no replacement 
was made for the 50 uL serum present in an assay. 
Iterefore the AOD produced by 1 umole, choline rmst be r 
corrected to: 
10.9 x 1.05 = 10.4 AU 
1 IU enzyme activity = 10.4 AU 
An enzyme activity of x IU =, 40D per minute 
10.4 
but under the conditions of the assay this enzyme 
activity (x) is in 50 uL serum. Therefore in 1L serum: 
Enzyme- Activity (IU/L) OD per minute x 20,000 
10.4 
Ihe factor to convert aOD per minute to enzyme activity 
in IU/L becares 1923. 
3.5 Investigation of the met , appropriate substrate 
allomtr 
sera from one individual homozygous for the usual form 
of cholinesterase and one homozygous for the atypical 
form were assayed f ive tires at each of six substrate 
concentrations, 0.0454,0.227,0.454,1.14,2.27 and 
4.54 mmol/L. The results are shown in , Fig. 3.4. The 
usual enzyme form exhibited substrate inhibition at 
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assay concentrations of succiny1choline in excess of 
1.14 mmol/L whereas the atypical enzyme had a 
cholinesterase activity which increased with substrate 
concentration throughout the range of succiny1choline 
concentrations tested. Reaction rate was maximal for the 
usual enzyme at a concentration of 1.14 mmol/L. Since 
this concentration differentiated well the between the 
two enzyme forms,, it was selected for use in subsequent 
assays. 
3.6 Investigation of the effect 'of altering the 
concentrations of the components of the colour reagent. 
Concentrations of reagents in the indicator 'reaction; 
aminophenazone, peroxidase, choline oxidase and phenoll 
were checked to ensure they were in excess and not 
inhibiting other stages of the reaction. 
In this series of experiments the concentrations Of 
reagents were those shown in Section 3.1 except for that 
of the reagent under test. This was altered to give 
values of 25,50,100j, 150 and 200% of the original. A 
serum sample from one of two individual homozygous for 
the usual cholinesterase variant was assayed five times 
at each concentration. Results are shown in Figs. 3.5- 
3.8. Cholinesterase activities were tested, - using an 
unpaired T-test, against- those obtained with the 
original reagent concentration to see if they' had 
changed significantly. The only reagent which produced 
significantly different results with 'a change in 
63 
concentration was choline oxidase. A reduction to 50 or 
25% of the original concentration gave significantly 
lower values for serum cholinesterase (P<0.001). As 
increasing the concentration of choline oxidase to 150 
or 200% did not further alter the results obtained the 
concentration of choline oxidase used was maintained at 
1 IU/mL colour reagent. 
3.7 7he final format of the metbod. 
Reagents: 
Calcium chloride: 7.8 g in 100 mL water. 
Aminophenazone: 6.0 g in 100 mL water. 
Buffer: Tris HCL, 50 mmol/Lj pH 7.4, containing 2g 
Triton X-100 detergent per litre. 
Colour reagent: 50 IU choline oxidase, 110 IU peroxidase 
and 10 mg phenol in So mL buffer to which is added 100 
UL each of calcium chloride and 4-aminophenazone 
solutions. The solution is stored at 40C and made 
freshly each week., 
Substrate: Succinylcholine chloride 25 mmol/L in water. 
This reagent is stable for up to 4 weeks when stored at 
40C. 
Procedure; 
50 UL of substrate and 1 mL of colour reagent are mixed 
in a cuvette and allowed to equilibrate at 370c for 3 
minutes,, 50uL- serum is added, mixed, and the rate of 
change in absorbance measured against a blank solution 
in which the serum has been replaced by buffer. 
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Enzyme activity, defined as micromoles of choline 
liberated per minute per litre of serum is determined by 
use of a factor: 
Enzyme activity (IU/L) = Ll OD per minute x 1923 
3.8 Imprecision: 
The within and between-run coefficients of variation for 
the assay were determined by replicate analysis of 
serum samples drawn from volunteer Elu homozygotes with 
normal cholinesterase activity. Serum for the assessrroýnt 
of the within batch coefficient 'of variation was 
analysed on the day of sampling. Serum for the 
assessment of between batch coefficient of variation was 
aliquoted and stored at -20 
0C until analysis. 
The within batch coefficient Of variation was 4.5% 
(n=20) for a sample with a mean 6holinesterase activity 
of 78 IU/L. 7he between batch coefficient of variation, 
assessed over a2 week period,, was 5.6% '(n=ll) for a 
sarriple with a mean cholinesterase'activity of 55.8 IU/L. 
3.9 Investigation of interferences. 
a) Lipaemia., 
A serum pool was made lipaemic by the addition of 
Intralipid such that lipid concentrations of 
approximately 2g/dL (twice the upper normal value for 
total serum lipids) and 4g/dL were obtained. However 
these samples could not be analysed 
spectrophotometrically due to their high initial 
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absorbance. In an attempt to produce physiological 
turbidity a volunteer ate a large fatty meal and samples 
were drawn for cholinesterase analysis before and one 
and a half hours post ingestion. The resulting samples 
were clear and turbid respectively. No significant 
difference in cholinesterase activity was observed 
between them using an unpaired T-test (p=0.165, n=5). 
Results are shown in Table 3.1. 
b) Icterus. 
Pooled serum (bilirubin 21 umol/L) was made icteric 
according to the method of Billing, Haslam and Wald 
[19711. Samples were prepared with bilirubin values of 
105,195 and 365 umol/L. Their cholinesterase activities 
were compared with the cholinesterase activity of the 
pooled starting serum using an unpaired T-test. Results 
are shown in Table 3.2. The samples with bilirubin 
values of 105 umol/L were not significantly' different' 
(p=0.364, n=6). However at a bilirubin levels greater 
than 195 umol/L there was a reduction in cholinesterase 
activity of 9.3% (p<0.05, n=6). At 365 umol/L there was 
a 23% reduction in cholinesterase activity. 
c) Haemolysis. 
The effect of haemolysis was investigated by comparing 
cholinesterase values in a serum sample from an Elu 
homozygote some of which -had 
been separateýa 
conventionally and the rest separated after the sample 
had been frozen and then thawed giving a serum sample 
which was moderately haemolysed (pink/red to the eye). 
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Replicate analysis of the two sanples showed no 
significant difference in the cholinesterase activities 
using an unpaired T-test (p=0.638, n=4). Results are 
shown in Table 3.3. 
3.10 Reference Range. 
Cholinesterase reference ranges were established by 
assaying serum obtained from male laboratory staff (ages 
23-45 years, n=39) and from nonpregnant women of 
reproductive age who were not taking oral contraceptive 
medication (n=50). No subjects were included who 
suffered from any condition likely to affect 
cholinesterase activity or who possessed genetic 
abnormalities identifiable by measurement of dibucaine 
-and fluoride inhibition. Two females were excluded from 
ua the original group, having been typed El El 
Succinylcholine activities are shown in Table 3.4 and 
Fig. 3.9. 
The reference ranges (man =2 SD) for serum from El 
u 
homozygotes (phenotypically usual since the presence of 
J/K variants cannot be excluded by biochemical tests) 
individuals are 45-86 IU/L for vales and 34-72 IU/L for 
females. These are significantly different (p <0.005), 
in agreement with reports for assays using other 
substrates (Siddell and Kaminskis 19751. The combined 
reference range for both sexes is 35-82 IU/L. 
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TABLE 3.1. 
AL'TTVMES IN SERUM SAMPLES TAKEN FROM A 
VOLUNTEER BEH3RE AND AFTER A FATTY MEAL. 
CHOLINESTERASE ACTIVITY (IU/L) 







rean 86.9 88.5 
--- - ------- --- -- ---------- - 
No significant difference p=0.165. 
=== -- ----- - -------- - 
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TABLE 3.2. 
LINESTERASE ACTI=ES IN A SERUM SAMPLE BEFCIRE AND 
AFTER THE ADDITICN OF BILIROM: 
BASAL A= THE ADDITION OF BILIRUBIN 




(IU/L) 71.2 71.2 71.2 57.7 
73.1 73.1 73.1 50.0 
76.9 71.2 71.2 53.8 
73.1 76.9 71.2 63.5 
73.1 69.2 65.4 55.8 
73.1 79.6 65.4 57.7 
rean 73.4 73.5 69.6 56.4 






There was no significant difference in the results after 
the addition of bilirubin up to 105 umol/L. At a 
bilirubin level of 195 umol/L and greater cholinesterase 
activity was significantly reduced. 
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7Nma 3.3. 
CHOLINESTERASE ACr=IES IN A SERUM SAMPLE BEFCRE AND 
AFTER HAEMOLYSIS: 
CHOLINESTERASE ACTIVITY (IU/L) 






mean 53.8- 53.4 
No significant difference (p=0.638). 
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TABLE 3.4 
SUCCINYDMI&INE ACTIVITIES IN HEALTHY, PHEMITYPICAILY 
USaAL INDIVIDURIS. 
































































3: 0 u 
Figure 3.1 
Equivalents of cholinesterase activity shown by 
spontaneous hydrolysis of a range of succinylcholine 
concentrations. 
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Symbols denotate mean + lSD. 
0 0.5 1.0 1.5 2.0 2-5 3.0 3.5_ 4.0,4.5 

















The relationship between cholinesterase activity & 
reaction rate. 
Open circles represent ultrafiltrated serum; r=0.995 
Closed circles - represent serum of average 
cholinest6rase activity; r=0.993 
Mean + lSD. n=5 
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CHOLINE ADDED TO REACTION 
MIXTURE (6moles) 
Figure 3.3 
Absorbance produced by the "addition of increasing 
amounts of choline chloride to the reaction mixture. 














Cholinesterase activities in sera frommindividual 
homozygous for the usual gene & one homozygous for the 
atypical gene measured at different succinylcholine 
concentrations. 
Closed circles represent serum from the EluElu 
individual. 
Open circles represent serum from the El a Ela, 
individual. 
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Mean +2 SD for 5 determinations. 
00-51.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 













Succinylcholine activity measured using ciour reagent 
with increasing am, inophenazone concentration. 
Mean+ 1 SD; n=5. 
5-1 10 , 15 - 20 -- 25 
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PEROXIDASE CONCENTRATION (IU/100ML) 
Succinylcholine activity measured using colour reagent 
with increasing peroxidase concentration. 
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CHOLINE OXIDASE CONCENTRATION (IU/mL) 
Figure 3.7 
Succiny1choline 
- activity measured with colour reagent with increasing choline oxidase concentration. 
Mean +1 SD. 

















Succinylcholine activity measured using colour reagent 
with increasing phenol concentration. 
Mean +1 SD; n=5 
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Succinylcholine activities of healthy individuals 
homozygous for the usual gene. 
Broken horizontal lines = mean +1 SD. ý-' 
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CHAPTER 4. - 
THE EVALUATION OF ME SUCCINYLCHOLINFr-BASED CHMINESITRASE 
ASSAY FOR THE INVESTIGATION CIL? SUCCINYLCHOLINE-INDOCED 
APNOEA. 
The aims of this section were to evaluate the clinical 
usefulness of the succiny1choline-based assay and to 
establish whether forms of cholinesterase exist which can 
hydrolyse substrates used in their assay but not 
succinylcholine. 
The succiny1choline-based assay for serum cholinesterase 
was compared with one using propionylthiocholine as the 
substrate. The latter method has previously been shown to 
be the best available for the identification of 
succiny1choline sensitive patients [Evans and Wroe 1978). 
In addition the assay was applied to the ipvestigation of 
a group of individuals who had experienced apnoea after 
the administration of succiny1choline but whose 
cholinesterase status was normal according to currently 
accepted biochemical criteria. 
4.1 Canparison of the -succinylcholine and 
propionyl activities of 'bealtby, phenotypically 
usual individuals. 
Conparison of'the succinylcholine and propiony1choline 
activities was performed using sera from the group of 
individuals" described in Chapter 3,, Section 3.10. 
Results are shown in Table 4.1'and Fig. 4.1. 
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4.2 Caqparison of the succinylcholine and 
Propionylthiocholine activities of individuals referred 
for assessment of cholinesterase status. 
The succiny1choline assay was applied to serum from 76 
patients and their relatives referred to the 
Cholinesterase Investigation Unit of this hospital 
during a three-month period. In the unit, routine 
investigation of cholinesterase status involves the 
measurement of propionylthiocholine activity at 25 0C and 
ascription of cholinesterase genotype on the basis of 
inhibition of benzoylcholine hydrolysis by dibucaine, 
sodium fluoride and Ro-0683. Samples are stored at -20 
0 C, which ensures long-term stability (Turner et al. 
19841. Results are shown in Fig. 4.2 and Table 4.2. 
The optimum dividing line for differentiation between 
succiny1choline sensitive and non sensitive patients 
using a propionylthiocholine assay has been reported as 
2.5 standard deviations (SD) below the mean for El u 
homozygotes [Dietz, Rubinstein and Lubrano 1973]. For 
succiny1choline this is 29 IU/L andl using this cut-off, 
the assay identified 19 of 22 patients who had either 
proven apnoea or a genetic variant associated with it. 
Three patients were missed. Two had an El a El 
k 
genotype 
which is not invariably associated with sensitivity to 
succiny1choline and one was a patient who had developed 
apnoea after being given succiny1choline but who 
subsequently proved to be normal by all routine 
biochemical criteria. He is included in the patients 
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considered later. one patient with a non-senstive 
genotype also had an activity of less than 29 IU/L but 
had not been exposed to succiny1choline so that no 
definite conclusions concerning sensitivity could be 
drawn. 
For the propionylthiocholine assay the -2.5 SD cut-off 
value is 1.64 IU/L and using this, it identified 14 of 
the 22 patients. of the eight who were missed,, four had 
an El a El 
k 
genotype and one was the patient with usual 
enzyme referred to above. The remaining three patients 
missed were all homozygous for the atypical form of 
cholinesterase, a genotype which is always associated 
with prolonged succinylcholine induced apnoea. In 
addition two had clinically proven sensitivity. No 
apparently non-sensitive patients were included in the 
"sensitive" group. 
4.3 Cmparison of succinylcholine and propionylthiocholine 
I 
activities of samples frcm iDdivickial with genetic 
abnormalities of cholinesterase. 
Eighty seven samples obtained f rom individuals with a 
wide range of genetic abnomalities were taken from a 
bank of material held by the Cholinesterase 
Investigation Unit. Samples were assayed using the 
succiny1choline-based assay and results coq: >ared with 
those obtained using propiony1choline as the substrate. 
Results are shown in Figs. 4.3 and 4.4 respectively and 
conbined in Table 4.3. 
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For the succiny1choline-based assay all individuals with 
genotypes invariably associated with sensitivity had 
activities of less than 29 IU/L. Of the 87 individuals 
investigated 22 had experienced an apnoea of 20 minutes 
or more. The succinylcholine-based assay identified 21 
of the 22. The patient missed had an El a El 
k 
genotype. ' 
one individual heterozygous for the usual and : the 
atypical form 'of cholinesterase was, included in the 
"sensitive' group, that is with a succinylcholine 
activity of <29 IU/L. This genotype is not usually 
associated with succinylcholine sensitivity -unless 
activity has been lowered by disease or pregnancy. 
However since the patient had been investigated only as 
part of a family study no -clinical assessment was 
available. Similarly of the 11 El a El 
k individuals 
included in this group only one'had been exposed to 
succiny1choline and been found to be sensitive. 
Figure 4.4 shows the propionylthiocholineýactivities on 
the 87 individuals. Using a cut-off of -2.5 SD (1.64 
IU/L) the assay failed to identify three individuals 
ffS 
typed ElaElap four typed ElaEl and one typed El El 
These genotypes are all associated with succinylcholine 
sensitivity. of 22 patients who developed apnoea eight 
had activities greater than the 1-. 64 IU/mL cut-off. one 
individual heterozygous; for the usual and the silent 
gene fell into the 'sensitive" -area (1.64 IU/ML). This 
is a genotype not usually associated with sensitivity in 
the absence of complicating factors. As he had not been 
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exposed to succinylcholine,, again no clinical 
interpretation was possible. Similarly no conclusions 
can be drawn concerning the 2 individuals of the El a El 
k 
genotype who were included in the sensitive group. , 
4.4 AWlication of the succinylcholine-based assay to 
biocbemical-ly normal indiviclial with apmea foUowiDg 
treatment with suc6inylcboline. 
Samples were obtained from 50 patients who had suffered 
an apnoea of 20 minutes or more after the administration 
of succinylcholine but on whom routine investigation of 
cholinesterase status gave normal results. The 
cholinesterase activities measured using the 
succiny1choline-based assay are shown in Table 4.4. 
Cnly one had an activity of less than 2.5 SD below the 
mean for Elu homozygotes (29 IU/L). 
The system described here uses a substrate concentration 
of 1.14 mmol/L which is much greater than that found 
pharmacologically. Schmidingere Held and Goedde (19661 
have calculated that the peak concentration likely to 
exist in the plasma after the administration of 
succiny1choline must be less than 50 umol/L. It is 
feasible therefore that within the group of 50 patients 
investigated here, there may exist individuals whose 
cholinesterase is able to hydrolyse succiny1choline at 
the relatively high assay substrate concentration but 
not at pharmacological concentrations, 7hey may possess 
an enzyme form with low affinity for succiny1choline 
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which cannot be detected either by this drug-based 
cholinesterase assay or by those using non- 
pharmacological substrates. 
Th investigate this possibility enzyme kinetic studies 
were performed on this group of patients and conpared 
with those performed on healthy Elu homozygotes. 
Individual samples were analysed in duplicate, where 
possible, using substrate concentrations of 0.045,, 
0.091,0.136,0.227,0.454 and 1.136 imnol/L. Km and Wax 
were calculated using a program based on one for non- 
linear regression (see Chapter 2,. Section 2.3). Using 
this program a range of equations, representing the 
commonly occurring kinetic mechanismso, are available-to 
apply to the data. Table 4.5 and Fig. 4.5 show 
typical results from a healthy El U horqozygote. These 
indicate that the enzyme obeys Michaelis-Menten kinetics 
and therefore this equation was used to analyse the 
results. Table 4.6 shows the Km and VMax values for 23 
healthy Elu homozygotes and for 30 patients suspected of 
an abnormality and upon whom sufficient serum -was 
available for analysis. Fig. 4.6 shows the Km values for 
the two groups. 
4.5 Discussion. 
In theory a method for the measurement of 
cholinesterase activity based upon succiny1choline 
hydrolysis will reflect the in vivo metabolism of the 
drug and therefore the duration of actiong more 
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precisely than one using a non pharmacological 
substrate. This assumption appeared to be substantiated 
following the work of Agarwal, Srivistava and Goedde 
(19751. They examined serum from 21 patients with 
clinical sensitivity but who had no cholinesterase 
abnormality. In six of these they were able to observe 
reduced catalytic activity when measured against 
succinylcholine. This they supposed indicated the 
existence of cholinesterase variants which were not 
apparent from the techniques in routine use. 
The succiny1choline-based assay described here is better 
than the one employing propionylthiocholine for the 
identification of sensitivity due either to genetic 
abnormalities or pathological reductions in 
cholinesterase activity. However no evidence has been 
found for the existence of new genetic variants. Cnly 
one of 50 cases biochemically normal but with clinically 
suspected sensitivity had an activity of less than 29 
IU/L (2.5 SD Below the the mean for Elu homozygotes). 
This patient was included in the 30 cases on whom there 
was also sufficient serum to assess the Km values. These 
were significantly different from the Km values obtained 
for 23 Elu homogotes, 107.8 (2 SD range 57.2-158.4) 
compared with 92.4 (2 SD range 38.8- 146.0). The Km 
values obtained for the group of biochemically normal 
patients who had experienced apnoea although higher than 
values for Elu do' not approach the Km values previously 
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estimated for the atypical cholinesterase (6 mmoi/L 
(Brown et al 19811) and therefore are unlikely to he 
those of a genotype unable to hydrolse succiny1choline. 
However it is possible that the slightly lowered 
affinity of their cholinesterase for succinylcholine may 
predispose them to the effects of other factors 
which may prolong apnoea. 
Nonetheless these observations contrast with those of 
Agarwal and his colleagues. Although there are 
significant differences in the two analytical systems it 
is unlikely that these are sufficient to explain the 
conflict. It is more probable that much of the 
explanation lies in their use of benzoylcholine as the 
routine substrate. Activities measured by this procedure 
have been shown to have minimal interpretive value 
[Evans and Wroe 19781. 
However the selection of patients who are genotypically 
normal with apparently abnormal reactions to 
succinylcholine is not without problems since clinical 
evaluation of the reaction to succinylcholine is 
uncertain. Two major problems beset the interpretation 
of cholinesterase findings on patients suspected of 
having experienced a prolonged succiny1choline induced 
apnoea. Anaesthetised patients often receive large 
numbers of drugs any of which may affect the ability to 
breathe. Secondly it is impossible to assess the cause 
of an apnoea without the patients myoneuronal conduction 
having been tested with a suitable stimulator. This can 
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help eliminate central depression of respiration as a 
possible cause. It must also be recognised that it is 
impossible for laboratory conditions ever to simulate 
entirely those prevailing at the time of the 
anaesthetic. Substrate concentration, the patients 
ventilatory state and the presence of other drugs which 
might influence cholinesterase will differ between the 
laboratory and the operating theatre. Nonetheless I feel 
that this work indicates that the number of patients 
sensitive to succiny1choline due to cholinesterase 
abnormalities which are failing to be recognised is 
small. In addition the routine use of a similar 
succiny1choline-based assay [Abernathy,, George and 
Melton 19841 has not yet led to the recognition of any 
new genotypes. These observations are in agreerrent with 
conclusions reached by Viby-Mogensen who, after careful 
review and follow up of 225 patients previously reported 
[Viby-Mogensen and Hanel 19781 with prolonged apnoea 
following succinylcholine, concluded that the number 




SUCCINYLaJOLIM AND PROPIONYLTHIOCHOLINE(PTCI) 
ACfIVITIES IN HEALTHY 10 DZYGMW. 
PTCI Succinylcholine PTCI Succinylcholine 
activity activity activity activity 
IU/ML IU/L IU/ML IU/L 
7.0 79.0 5.35 57.7 
5.6 65.4 4.4 53.8 
5.1 67.3 3.4 48.0 
4.0 50.9 4.4 44.2 
6.5 71.2 3.2 38.5 
4.0 55.8 5.8 61.5 
5.1 66.4 4.7 55.8 
3.4 49.0 3.4 44.2 
4.3 48.1 4.6 44.2 
2.6 44.2 3.7 46.2 
4.2 55.8 5.5 61.5 
4.9 62.5 4.2 50.0 
3.8 53.8 4.8 51.9 
3.4 45.2 2.4 44.3 
3.75 40.0 5.1 66.4 
4.95 50.2 3.9 53.8 
6.35 67.4 4.2 55.8 
4.7 57.8 5.3 62.5 
4.1 42.4 5.2 43.3 
4.0 42.4 4.3 66.4 
3.6 42.2 5.6 65.4 
3.2 40.4 3.5 51.9 
5.5 61.5 5.3 63.4 
5.3 63.5 5.2 63.4 
3.85 46.2 4.4 67.3 
5.85 65.4 7.2 80.8 
4.15 50.0 4.3 59.6 
3.85 59.6 4.5 46.2 
3.8 57.7 4.3 57.7 
5.1 44.2 6.0 67.3 
4.0 50.0 4.6 59.6 
3.7 44.2 3.6 48.1 
3.4 40.4 6.5 75.0 
3.7 59.6 6.0 80.8 
5.5 69.2 5.2 69.2 
4.7 62.3 4.9 55.8 
4.5 61.6 5.3 62.5 
4.9 63.5 4.1 60.6 
6.0 75.0 7.0 76.0 
6.6 80.6 5.2 63.5 
5.4 75.0 5.5 80.8 
5.6 72.2 3.6 60.0 
7.2 80.8 7.1 85.6 
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ACrIVITIES IN EEALTHY El 
PTCI Succinylcholine PTCI Succinylcholine 
activity activity activity activity-, 
IU/ML IU/L IU/ML IU/L 




COMPARISON OF THE SUCCINYWHOLINE AND 
PROP IONYLTHIOCHOLINE (PTCI) ACTIVITIES OF 76 PATIENTS 
REFERRED FOR THE ROUTINE INVESTIGATION OF CHOLINESTERASE 
STATUS. 
Genotype PTCI succiny1choline Apnoea 
activity activity 
IU/ML IU/L 
-------- - --- - 
El u El u 6.0 85.2 
El u El u 3.3 57.3 
El El 1.05 6.8 YES 
Ela El 
a 3.65 52.1 - El El 1.25 7.7 - u a El El 4.25 71.2 - 
Ela Ea 4.45 62.5 - 
El El 2.15 12.5 YES 
El El 
a 
4.1 58.8 - 
El El 
u a 
5.0 51.5 - 
El E 3.0 35.7 - 
El El 3.3 65.3 - 
E El 6.2 87.9 - a a E E 1.2 6.1 YES 













El El 1.55 9.3 YES 
El a El 
a k 
3.1 39.1 
El El 3.65 45.5 
E E 1.5 15.1 YES U u El El 4.3 61.8 - 
El El 2.55 33.4 - 
El Ela 
u a 
3.95 39.1 - 
El E 2.85 48.3 - 
El El 
a 
5.1 74.4 - 
El E 1.15 5.4 YES 
ElUElU 5.75 87.4 YES 
EluE-lu 
U 
5.74 69.6 - 
El ElU 6.2 83.7 - 
Elu-E a 2.9 35.2 - 
El a El 
u 
2.35 27.9 - 
Ela El 4.3 54.0- - 
El a 1.2 6.4 - ia ElUE 
_ 
5.15 59.3 - 
El u El u 5.7 75.8 - 
El Ela 4.85 59.9 - 
E E 3.5 61.8 - u u El Ej; 5.25 69.3 - u El El 6.9 71.3 - 
EluElu 5.65 77.8 - 
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- TME 4.2 contd. 
COMPARISON OF THE SUCCINYLCHOLINE AND 
PROPIONYLTHIOCHOLINE (PTCI) ACTIVITIES OF 76 PATIENTS 
REFERRED FOR ROUTINE INVESTIGATION OF CHOLINESTERASE 
STATUS. 
Genotype PTCI Succinylcholine Apnoea 
activity activity 
Iu/InL IU/L 
El u El u 4.7 66.5 
E E 2.9 37.4 u a E El 
a 4.2 50.5 E El 3.1 36.2 a E El 2.9 36.7 u a El El a 
4.7 49.7 
El El 2.05 9.6 YES 
El E 3.1 43.8 - 
E El 4.1 53.9 - a u Eu El 
s 
3.6 39.9 - 
El El 
s 
2.8 37.0 - 
El El 3.45 40.8 - ia El E_ 
u u 
1.0 - 14.0 
El El 3.05 42.3 - 
El ,a 3.8 46.5 
E El 
f 4.95 73.7 
El El a 2.0 16.6 
El Ela 3.3 43.6 









El E u a 
3.45 58.0 
El El 4.85 54.2 
El uEu 
3.15 40.7 
E El 3.9 47.4 




El 1 0.9 14.5 YES 
El aa 
0.85 12.0 
E El 1.05 7.5 YES u u El E a a 
3.65 46.4 
El E 0.95 6.0 
Apnoea noted was greater than 20 minutes. 
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7N3w 4.3. 
SUCCINYLCHOLINE AND PROPIONYLTHIOCHOLINE ACTIVITIES IN 
INDIVIDUALS WITH GENETIC ABNORMALITIES OF CHOLINESTERASE. 
Genotype Succinyl- PTCI Genotype succinyl- PTci 
choline choline 
activity activity activity activity- 
IU/L IU/ML IU/L IU/ML 
ElaEl 15.4 1.64 El a Ela 3.9 0.91 
25.1 2.3 5.8 1.17 
34.7 3.7 2.9 1.48 
24.6 2.7 5.8 2.0 
34.5 3.3 7.7 2.04 
31.7 3.2 4.8 1.38 
19.2 2.2 2.9 -0.88 
32.5 3.3 -4.8 1.47 
44.1 4.0 2.9 1.09 
19.2 1.8 13.5 1.82 
18.8 2.1 4.8 1.29 
18.3 1.3 6.8 1.05 
29.2 2.8 7.7 1.25 
39.1 3.1 6.1 1.2 
45.5 3.7 13.0 2.15 
27.9 2.4 3.6 1.45 
14.0 1.0 9.3 1.4 
25.5 2.6 8.2 1.5 
5.3 1.15 
mean: 27.74 2.62 6.4 1.2 
SD: 9.45 0.85 ---- ------ -- 
------- ---- mean: 6.31 1.39 SD: 2.99 0.36 
El s Els <2.0 <0.1 
ElaEl f 23.1 1.8 EluEls 36.7 3.1 
15.4 1.4ý 43.3 3.7 
15.4 1.4 30.5 1.2 
19.2 38.3 2.7 
5.8 1.1 46.2 3.4 
23.7 3.1 42.8 3.5 
10.5 1.1 48.1 3.9 
25.5 2.8 43.8 3.1 
mean: 17.33 1.83 mean: 41.21 3.08 
SD: 6.88 0.76 SD: 5.73 0.85 
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TABLE 4.3 cmtd. 
SUCCINYLCHOLINE AND PROPIONYLTHIOCHOLINE ACTIVITIES IN 
INDIVIDUALS WITH GENETIC ABNORMALITIES OF CHOLINESTERASE. 
























mean: 46.62 3.82 
SD: 14.96 1.21 
EluEl 









El a El s 6.0 1.0 
4.0 0.5 
5.8 1.2 
5.; 9 0.85 
<2.0 0.85 
3.9 0.95 
mean: 4.27 0.91 
SD: 2.30 0.24 
fs -------- 
El El 19.2 
-- 
1.7 
mean: 54.44 4.76 
SD: 13.29 1.13 
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7%BLE 4.4. 
CHOLINESTERASE ACTIVITIES IN BIOCHEMICALLY NORMAL PATIENTS 
WITH APNOEA AFTER TREATMENT WITH SUCCINYLCHOLINE. 
Duration of Propionylthiocholine Succiny1choline 
apnoea activity activity 
minutes IU/ML IU/L 
2.9 50.6 
75 3.6 45.9 
120 6.5 75.3 
3.7 66.6 
30 4.5 67.3 
60 4.6 59.6 
40 5.1 54.5 
6.0 58.8 
4.6 64.1 
35 5.7 65.7 
25 3.6 56.1 
60 4.0 40.6 
4.0 78.2 
3.8 45.3 
30 5.2 60.4 
30 2.5 27.8 
3.0 32.8 
90 4.5 59.6 
25 4.7 47.6 
50 3.7 52.9 
3.1 40.6 
30 4.5 83.8 
3.5 45.9 
30 5.1 69.5 
4.5 73.3 
4.1 55.5 
20 3.4 44.0 
60 5.7 64.6 
30 4.7 53.4 




45 6.1 80.1 
4.0 57.8 
90 5.7 68.9 
45 6.3 74.2 








Th= 4.4 cmtd. 
CHOLINESTERASE ACTIVITIES IN BIOCHEMICALLY NCRMAL PATIENTS 
WITH APNOEA AFTER TREATMENT WITH SUCCINYLCHOLINE. 
Duration of Propionylthiocholine Succinylcholine 
apnoea activity activity 
minutes IU/ML IU/L 
--- - ---------------- - ------------------ - -- -- 
180 4.0 51.5 
20 2.1 38.5 
45 4.5 68.0 
120 8.6 75.2 
4.1 42.4 
2.6 30.9 
* Length of apnoea unstated but greater than 20 minutes. 
a Activity more than 2.5 SD below the mean for Elu 
homozygotes. 
All patients had cholinesterase inhibitor numbers 
characteristic of the usual phenotype as determined by 
inhibition of benzoylcholine hydrolysis by dibucaine, 
fluoride and Ro 02-0683 (see text). 
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TABLE 4.5. 
TYPICAL VEL CONCENTRATION RESULTS 
_. 
QCITY VERSUS SUBSTRATE 





------ -- -- 
1.136 60.4, 64.6 
0.454 51.7, 55.3 
0.227 45.4, 46.9 
0.136 37.9, 37.1 
0.091 30.0, 32.1 
0.045 23.2, 19.4 
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mum 4.6. 
Fin AND Vmax VALUES FOR HEALTHY ElU HOMOZYGOTES AND FOR 
PATIENTS WITH NORMAL CHOLINESTERASE STATUS BUT WHO 
DEVELOPED APNOEA FOLLOWING TREATMENT WITH SUCCINYLCHOLINE. 
Elu Homozygotes Biochemically normal patients 
with apnoea 
Km Wax Km Vmax 
umol/L IU/L umol/L IU/L 
142 74 129 
96 79 116 
87 73 62 
82 88 110 
87 71 122 
78 63 82 
82 61 129 
89 57 97 
73 49 99 
96 97 118 
62 72 104 
70 99 104 
86 50 107 
87 76 62 
63 81 71 
74 92 83 
84 45 82 
55 49 106 
83 71 95 
144 101 128 
136 53 120 
137 73 102 
133 55 97 
- 195 
92.4 70.8(mean) 113 


































The Km results for the two groups are significantly 














ell 1% 4 -% 
Comparison of cholinesterase activities of healthy Elu 
homozygotes measured using succinylcholine and 
propionylthiocholine substrates. 
0 1.0 2.0 3.0 
-4-0 ý5-01 
6.01 7.0118.0 
PROPIONYLTHIOCHOLINE ACTIVITY' OU/MU 
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Figure 4.2 
Comparison of enzyme activities of 76 subjects referred 
for routine investigation of Cholinesterase status. 
Circleý Individuals with succinylcholine sensitivity. 
Crosses Individuals witb at, least one usual gene. 
Circles annotated AK = El"#Elr' homozygotes. 
Circled symbols = subjects treated with succiny1choline 
who developed apnoea. 
it 
jr 
Shaded bars denote the reference interval for Elu 






EuEu EuE43 EuEf 
Figure 4.3 
E'JE' EcEk,? * EcEo* EcEf * EoEs * EfEt, ESE$* 1 1,1 111111111 
Cholinesterase genotypes 
Sucinyl choline activities of 87 subjects with unusual 
cholinesterase genotypes. 
Circled symbols indicate patients treated with 
succinylcholine who developed apnoea. 
Shaded bars denote the Elu homozygote refernce range. 
Heavy and broken horizontal lines denote mean +2 SD. 
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uuuaus EEEEE Elf EUE, EoEkl? EOEo* EoEf* EC'ES, * EfEt, ESE$* 
Cholinesterose genotypes 
Figure 4.4. 
Propionylthiocholine activities of 87 subjects with 
unusual cholinesterase genotypes. 
Circled symbols indicate patients treated with 
succiny1choline who developed apnoea. 
Shaded bars denote the Elu homozygote refernce range. 










Graphs of - substrate concentration vs velocity & it's 
reciprocal for an individual homozygous for the usual 
gene. 
Mean of duplicate determinations at each substrate 
concentration are shown. 
0 0.2 0-4 0-6 0.8 1.0 1.2 
Substrate concentration (S) (mmol/L) 































Michaelis-Menten constants in healthy Elu homozygotes 
and patients normal by current biochemical criteria but 
who had experienced apnoea after treatment with 
succiny1choline. 
Heavy and broken horizontal lines = mean+ 1 SD. 
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CHAPTER 5 
INVESTIGATION OF THE KINETICS OF THE SUCCINYLCOOLINE- 
CHOLIMOTMASE REAMON USING THE NEWA DESCRIBED ASSAY. 
A. Investigation of the type of kinetics exhibited by the 
interaction between ch6linesterase and succinylcholine. ' 
Kinetic studies on plasTra and purified preparations of 
cholinesterase have demonstrated that the hydrolysis of 
choline esters does not follow Michaelis-Menten kinetics 
(Heilbron 1948, Berry 1960, Main 1983 and Wetherell and 
French 1986]. Preliminary kinetic studies, performed 
whilst setting up the suciny1choline-based assay for 
cholinesterase and during it's application to patients who 
developed sensitivity to thedrug, indicated that when 
hydrolysing succinylcholine, cholinesterase did obey 
Michaelis-Menten kinetics. In order to clarify this the 
work was extended and samples were analysed using a wider 
range of substrate concentrations. 
5.1 Kinetic studies using the succinylcholine-based assay 
for serum cholinesterase. 
The following samples were analysed 
a) serum from 3 individuals typed El u El u (2 male and 
1 female). 
b) serum from one individual typed ElaEla. 
c) purified cholinesterase from two sourcese Sigma 
Chemical Company, Poole (a relatively crude 
preparation, method undisclosed) and Calbiochemp 
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Cambridge (cholinesterase purified 10,000-fold by-the 
method of Haupt et al. [19661). 
Each sample was analysed in quadruplicate over a range 
of 'in assay" substrate concentrations 0.0454,0.0909, 
0.1361 0.227,0.454,1.136,2.272,3.41,4.54,6.81, 
9.088,13.62,22.7 and 45.5 mmol/L. 
Results for all samples areýshcwn in Figs. 5.1-5.6. Km 
and Wax values calculated from*this data are shown- in 
Table 5.1. 
In experiments using the usual enzyme succinylcholine 
activity starts to increase rare rapidly at substrate 
concentrations greater than 4.54 mmol/L allowing the 
calculation of two Km and Vrax values, one set with low 
the other with high values for both parameters. One, 
interpretation of this data is that succiny1choline is 
hydrolysed by usual cholinesterase at two sites and by 
the atypical form at only one. 
5.2 Discussion. 
The hydrolysis of succiny1choline by human plasma or 
purified human cholinesterase does not follow normal 
Michaelis-Menten kinetics when substrate concentrations 
greater than 4.54 mmol/L are also studied. 
The observed kinetics are consistant with previous 
observations using other substrates, that cholinesterase 
has two active sites (Heilbron 1958, Berry 1960 and 
Weatherall and French 19861 the presence of which have 
been interpreted in different ways: 
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a) that two enzymes exist both capable of hydrolysing 
the substrate (Heilbron 1958). 
b) that enzyme activation occurs at high substrate 
concentrations [Hastings 19661. 
c) that the - enzyme molecule contains a modifier or 
allosteric site [main 19831. 
Since the two sites are present whether plasma, crude or 
very pure preparations of cholinesterase are used as the 
source of the enzyme it is unlikely that they arise from 
the presence of two enzymes. 
The clinical dose of succiny1choline for adults is 1 
mg/kg and has been estimated to produce plasma levels of 
approximately 50 umol/L (King, Silk and Whittaker 19781. 
This concentration would be hydrolysed by the Kml site 
of cholinesterase. The kinetic constant obtained for the 
atypical cholinesterase approaches those obtained for 
the . '_ Km2 site of usual cholinesterase. The value 
of 6.922 mmol/L is in agreement with that found 
previously (6.0 mmol/L) [Brown et al. 19811 and 
provides confirmation that the long-lasting paralysis in 
a person with atypical cholinesteraseds due to the 
inability of that cholinesterase to hydrolyse 
succiny1choline at pharmacological concentrations 
[Kalow 19591. Sufficient samples have not been analysed 
to demonstrate whether this difference between atypical 
and usual cholinesterase is due the absence of the Kml 
site but nonetheless the work is consistant with that of 
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Lockridge and La Du [19781 who concluded that the 
atypical enzyme is a structurally modified form of 
cholinesterase. 
B. CaTqparison of the xml values'obtairw-d in-this study 
with those reported in the literature. 
The range of Kml values obtained in, this study for usual 
cholinesterase is 92.4 + 26.8 umol/L (mean + 1SD), n= 23. 
other workers have'reported lower values (see Table 5.2). 
Possible explanations --for these findings have been 
examined. The assay calibration was checked, using-,, an 
alternative choline salt bought specifically for- the' 
purpose and components of the assay system were 
investigated to see if they act as -ýcholinesterase 
inhibitors. 
5.3 Investigation of the assay calibration. 
The assay calibration (see Chapter 3 section 3.4) was 
reassessed using choline iodide instead of choline 
chloride. In addition 50 uL of buffer was added to the 
reaction mixture to substitute for serum usually 
present, rather than correct for it in the calculation, 
as in the original calibration. Five quantities of 
choline 0.5,12.5,25,50 and 100 rmles were added to 
the colour reagent and the maximum amount of colour 
produced recorded. Results are shown in Fig. 5.7. The 
absorbance produced by 100 nmoles choline iodide 
(calculated from the y on x regression equation derived 
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f rom the data shown in Fig 5.7) was 0.974. From this 
value the factor to convert OD per minute to enzyme 
activity is 2053. This was derived in the same way as 
the original factor of 1923 but is 7% higher. Thus 
calibration with choline iodide would, give higher Km 
values. 
5.4 Studies of potential inhibitors of cholinesterase in 
the assay system. 
Augustinsson [19481 stated that both aminophenazone and 
phenol were inhibitors of cholinesterase. To investigate 
whether inhibition occurred at concentrations present in 
the succiny1choline assay system, aminophenazone and 
phenol were added to an assay system for cholinesterase 
using propionylthiocholine as the substrate. They were 
added in amounts which kept their ratio to serum 
equivalent to that in the succiny1choline assay system. 
Serum samples from 6 El U homozygotes with a range of 
cholinesterase activities were analysed in duplicate 
before and after the addition of aminophenazone or 
phenol to the assay system. Results are shown in Table 
5.3. Cholinesterase activity was significantly lower 
after the addition of aminophenazone (p<0.001, using. a 
paired t-test) but there was no significant difference 
in the results following the addition of phenol 
(p--0.142). Aminophenazonel at concentrations used in the 
succiny1choline-based assay system, therefore inhibited 
serum , cholinesterase whilst phenol 
did not., The 
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inhibition was further examined by applying the 
succiny1choline-based assay to serum from an El u 
homozygote using a range of succiny1choline 
concentrations, before and after reducing the 
aminophenazone concentration to 25% of the original 
value . Results are shown in Fig. 5.8 and Table 5.4. As 
the concentration of aminophenazone is increased in the 
assay system both Km and VMax are reduced, it appears 
therefore to be an uncompetitive inhibitor of 
cholinesterase. 
5.5 Discussion. 
Calibration with choline iodide yielded a- factor 
producing results 7% 'higher thari the original 
calibration with choline chloride. it is difficult to 
explain these findings. Such results might occur if 
choline iodide had absorbed water'. However -this is 
unlikely since the' choline iodide was bought 
specifically 'for the calibration procedure and is less 
hygroscopic than the chloride [Dittmer and Wells 19691. 
Impurities in either salt' might account for the 
discrepancy but both reagents were Analar' grade and 
stored dessicated at 40C until 'use. If the higher 
calibration value, was used for the assay Km values would 
also be higher. 
Aminophenazone is an uncompetitive inhibitor of 
cholinesterase and as such it's'presence would decrease 
rather than increase the observed Km. Neither 
ill 
calibration with choline chloride nor the presence of 
aminophenazone appear therefore to be responsible for 
the higher Km values obtained using this assay system. 
Tris [Pavlic 19671 and Triton X-100, [Barenghi et al. 
19861 have previously been reported to- inhibit 
cholinesterase. Their omission would decrease the 
observed Km only if they proved to be competitive 
inhibitors of cholinesterase. . However they', "are both 
essential components of the assay system. 'Triton X-100 
is required for the proper development of the coloured 
dye product [BCL Ltd., choline oxidase -., product 
information] and Tris is preferred to phosphate buffer 
as use of this latter buffer causes precipitation of 
calcium, another necessary assay component. 
The problem of the presence of potential inhibitors in 
this type of assay system can be avoided by performing 
the assay in two stages involving: 
1. The enzymic hydrolysis of succinylcholine. 
2. The inhibition of cholinesterase by physostigmine 
and the determination of the choline produced. 
This approach was taken by Abernathy, George and Melton 
(19841. However -it is not without problems. Timing of 
the enzymic hydrolysis is critical- as is complete 
inhibition of cholinesterase activity. Inhibition 'of 
cholinesterase activity is achieved using a high 
concentration of physostigmine which can lead to 
contamination of other Cholinesterase assays even with 
the use of good laboratory technique. 
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The Kin value f or the usual f orm of cholinesterase using 
this technique was 53 umol/L [Abernathy, George and 
Melton 1984] however this estimate was obtained 
following one experiment on pooled plasma. other direct 
estimates (Wakid, Tubbeh and Baraka 1985 and Goedde, 
Held and Atland 19681 were derived similarly. This study 
reports the mean Km derived from separate analysis of 
samples from 23 El u homozygotes, a more reliable method 
of estimating a value representative of the whole 
population. 
In addition the Km derived in the present study is 
consistant with clinical observation. The plasma 
concentration of succiny1choline resulting from a 
typical dose has been reported to be less than 50 





The velocity of the reaction between cholinesterase and 
succiny1choline can be calculated. The mean values of 
Vmax and Km for Elu homozygotes have been estimated 
earlier (see Table 4.6). Values were 70.8 IU/L and 92.4 
umol/L respectively and thus the velocity of the 
reaction is 24.8 IU/L (umoles of substrate converted per 
minute per litre of serum. If pharmacological 
concentrations of succiny1choline are 50 umol/L of serum 
they should be hydrolysed in 2.02 minutes. The duration 
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of action of succiny1choline in vivo is 2-5 mins thus 
the kinetic values obtained in this study are conpatible 
with clinical observations. 
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TABLE 5.1 
Km AND Vloax VALUES FCR THE HYEROLYSIS OF SUCCINYI43MIINE 
BY "I'LINESTERASE AT SITE1 AND 
Sample Km1 Vmaxl Km2 VMax2 
mmol/L IU/L rmnol/L IU/L 
EluElu 0.144 101 7.92 226.3 
EluEl u 0.137 72.5 10.80 231.5 
El u El u a 
0.136 52.7 10.77 253.5 
El Ela 6.922 171.9 - - 
Sigma 
purif ied 










En VALUES FOR 
PREVIOUSLY IUKPCFMKD. 
KM VALUES 
SUCCINYLCOOLINE AND "B"WeINESTERASE 
AUMORS 
38 uml/L Goeddeo, Held and Atland 1968 
53 umol/L Abernathy,, George and Melton 1984 
30 uml/L Wakid, Tubbeh and Baraka 1985 
22 umol/L Goedde, Held and Atland 1968 
6 umol/L King and Griffin 1973 
** Fin calculated indirectly using the pI50 from 
succiny1choline inhibition studies. , 
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TABLE 5.3. 
21VESTIGATION OF INEUMMON OF BY 
ANIHOPSENUME AND ROM. 
PTCI activity PTCI activity PTCI activity 
. with added with added 
aminophenazone phenol 
IU/ML IU/ML IU/ML 
---------------- -- 
1.54 1.40 1.75 
4.15 3.79 4.29 
5.92 5.46 5.88 
1.41 1.16 1.32 
7.65 7.24 7.76 








KM AND VbMX VALUES CBTAINED AFTER PJMMNG THE 
ANIHOPEMNAZCNE CONCERMAMM 
1. KM Values (nml/L): 
Sanple. original Colour 




1 137 190 
2 136 159 
3 133 170 
4 144 193 
5 139 192 




2. Vmax (IU/L): 
Saffple Original Colour reagent 
colour with decreased 
reagent aminophenazone 
1 72.5 96.2 
2 52.7 55.5 
3 73.9 75.9 
4 101.1 112.1 
5 49.5 61.7 
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Plot of velockty against log succinylcholine 
concentration for serum from 3 individuals homozygous 
for the usual cholinesterase gene. - 
symbols = mean of 4 replicates for each individual. 
-2 -1 012 
LOG [SUCCINYLCHOLINE1 IN ASSAY 




Lineweaver-Burk plot for serum from one individual 
homozygous for the usual gene. 
Mean of 6 determinations at each substrate 
concentration are shown. 
















Figure 5.3 -, 
Plot of veloioty against log succiny1choline 
concentration for serum from individual homozygous for 
the atypical cholinesterase gene. 
Mean ±1 SD; n=5 
-1.0 0 1.0 2-0 
LOG (SUBSTRATE] mmol/L 
n OJO 
Figure 5.4 
Lineweaver-Burk plot for the serum from an individual 
homozygous for the atypical gene. 
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Plot of velocity against log succinylchlone 
concentration for purified cholinestease. 
Circles = Sigma cholinesterase (Crude preparation) 
Closed circles = Calbiochem Cholinesterase. 
Purified 10,000 fold. 
Horizontal lines 11 SD. n=6 
-2 -1 012 
LOG [SUCCINYLCHOLINE1 IN ASSAY 
(substrate concentration mmol/L) 
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Figure S. 6 
Lineweaver-Burk plot for. purified cholinesterase. 
open circles = Sigma enzymes (crude preparation) 
Closed circles = Calbiochem Enzyme. 
Purified 10,000 fold. 
Mean of 4 determinations at each substrate 
concentration. 
-12 -10 -8 -6 -4 -2 02468 10 12 
'IS (L/mmol) 
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Absorbance produced by the additi8n of increasing 
an=nts of choline iodode to the reaction mixture. 
Mean+ 1 SD; n=4 
20 40 60 80 100 






Lineweaver-Burk -plot for serum from 1 subject before 
and after reducing the aminophenazone concentration. 
Closed circles= original colour reagent. 
open circles = after reduction of aminophenazone 
concentration. 
mean of determinations at each substrate 
concentration. 




THE SUCCINYWHOLINE-BASED ASSAY IN LIVER DISEASE. 
Cholinesterase is synthesised in the liver and therefore 
can be used as a test of liver function in the same way as 
albumin. In Europe it is a frequently used test but in 
this country it has only been advocated in specific 
circumstances, for example in the surgical treatment of 
cirrhosis [Hunt and Lehmann 19601 and the monitoring of 
liver transplants [Evans and Lehmann 19711. 
I have compared cholinesterase activities measured using 
succiny1choline with those obtained using conventional 
substrates; propionylthiocholine, benzoylcholine and 
butyrylthiocholiner in patients with clinically graded 
liver disease. A further comparison has been made between 
succinylcholine activity and serum albumin which is the 
most widely used test of the liver's synthetic ability. 
6.1 Patients. 
Blood samples were obtained f rom, . 
54 patients with 
established liver disease in whom inhibition studies 
revealed no evidence for the presence of genetic 
variants of cholinesterase. These comprised 26 women and 
28 men age range 19-72 years. The severity of the liver 
disease was assessed by a modification of the procedure 
originally described by Child (19641 and modified by 
Pugh et al. (1973). It is based upon both clinical signs 
and laboratory measurements i. e. the presence or absence 
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of encephalopathy and ascites, serum concentrations of 
albumin and bilirubin and prothrcmbin time. The system 
scores 1,2 or 3 points for increasing abnormality of 
each of the five parameters used. Patients whose liver 
function remains good and where scores total 5 or 6 
are designated grade A. Scores of 7,8 or 9 are equated 
with grade B disease and patients with 10-15 points, 
and therefore with poorest hepatic function,, are 
designated grade C. Full patient details are shown in 
Table 6.1. All diagnoses were histologically proven by 
needle or open liver biopsy, the biopsies being reported 
by an independant histopathologist. Confirmative 
immunology was performed where appropriate. 
6.2 Cholinesterase activities in patients with liver 
disease. 
Cholinesterase activities are shown in Table 6.2. 
The results expressed as standard deviations from the 
mean for Elu homozygotes and the patient's corresponding 
modified Childs grading are shown in Table 6.3 and Fig. 
6.1. 
of the 54 patients 17 were found to have low activities 
(more than 2 standard deviations below the mean for El u 
homozygotes) using propionylthiocholine,, 19 using 
benzoylcholine and 20 using butyrylthiocholine. However 
using succinylcholine there were 31 low activities. 
Seventeen patients had low activities by all four 
procedures including all 10 who were graded C. 
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The relationship of abnormally low cholinesterase 
values to clinical grading of liver disease is shown in, 
Table 6.4. 
6.3 Carparison of albumin and succinylcholine activity in 
patients with liver disease. 
Serum albumin and succinylcholine activity were measured 
in all patients. Albumin concentrations are shown in 
Table 6.1 and succinylcholine activities in Table 6.2. 
low albumin values ( less than 30g/L, the lower limit of 
the reference raTige) were found in 11 of the 54 patients 
and comprised 7 individuals with grade C and 4 with 
grade B disease. Low succinylcholine activities ( less 
than 35 IU/L) were found in 31 patients made up from 6 
with grade A, 15 with grade B and all 10 individuals 
with grade C liver disease. 
Fig. 6.2 illustrates the relationship between 
succiny1choline activity and serum albumin 
concentration. 
6.4 Dianwion. 
All assays appear to be able to differentiate severe 
liver disease (Childs grade C) but the succinylcholine- 
based assay was able to identify more patients with 
moderate and mild disease. 
This study demonstrates that there is little difference 
between conventional assays in their ability to assess 
hepatic function in agreement with the observations 
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of others [Prellwitz, Knapp and Muller 19761. However a 
succinylcholine-based assay is superior. 
Reasons why succiny1choline activity is a better index 
of hepatic function are,, at present,, speculative. 
Decreased plasma cholinesterase activity may reflect not 
only impaired synthetic ability by the liver but also 
possible inhibition by metabolites accumulating 
secondary to liver disease. Succinylcholine hydrolysis 
may be more susceptible to such factors. 
Cholinesterase activity, irrespective of substrate, is a 
better index of severity of liver disease than albumin. 
It may reflect additional aspects of liver function in 
particular short term changes in synthetic capacity: 
cholinesterase has a shorter half life than albumin, 3.4 
to 16 days (Brown et al. 19811 compared with-17 to 26 
days (Eastham 19781. 
Currently measurement of serum albumin is offered by 
most clinical chemistry laboratories in the profile of 
biochemical tests of liver function which are often 
requested routinely in the non-specific investigation of 
illness. Albumin may have advantages over cholinesterase 
in this situation in that it is an acute phase protein 
responding to many aspects of disease and is required 
to correctly interpret total calcium 'measurements. 
However if an assay is required specifically for the 
assessment or monitoring of liver disease a 
succinylcholine-based assay of plasma cholinesterase 
could well become a more desirable choice. 
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TABLE 6.1 ý -' 
FULL CLINICAL DETAILS OF PATIERM WITH LIVER DISEASE. 
Patient Sex Age Diagnosis Bili ALT Alb PT Ascites Ence- 
No. yrs + Childs umol IU g/L sec phalo- 
grading /L /L pathy 
1 m 48 AC 27 65 29 15/ ++ + 
[B] 12" 
2 m 51 CC 12 31 39 12/ - - 
(A] 12, 
3 F 58 CC 31 58 38 12/ - - 
(A] 12 
4 F 63 PBC 27 28 39 12/ - - 
[A] 12 
5 m 19 cc 7 19 39 12/ - - 
[A] 12' 
6 F 61 PBC 10 48 43 12/ - - 
(A] 12 
7 m 50 SC 92 46 34 14/ + - 
(B] 12 
8 F 59 PBC 68 75 31 15/ + 
[B] 12 
9 m 37 CAH +C 19 28 32 16/ ++ 
(B] 12 
10 m 21 CAH +C 9 31 42 12/ 
(A] 12 
11 m 22 CC 43 38 18 18/ ++ 
[C] 12 
12 F 38 CAH 12 16 38 12/ 
[A] 12 
13 m 61 AC 25 31 27 12/ ++ 
[B] 12 
14 F 50 CPH 13 62 41 12/ - 
[A] 12 




Patient Sex Age'Diagnosis Bili ALT Alb PT Ascites Ence- 






g/L sec phalo 
pathy 
16 F 66 PBC 24b' 39 22 12/ + 
(B] 12 
17 F 48 PBC 210 71 30 20/ + 
[B] 12 
18 m 63 AC 33 39 32 14/ ++ 
[B] 12 
19 F 59 CAH 9 11 43 12/ 
[A] 12 
20 F 71 CAH +c 23 9 31 14/ + 
(B] 12 
21 m 72 CAH 10 19 42 12/ 
(A] 12 
22 m 61 AC 35 25 33 21/ ... 
[C] 12 
23 m 48 AC 16 61 32 18/ ++ 
(c) 12 
24 F 66 PIC 8 8 43 12/ + 
(A] 12 
25 m 23' cc 12 110 40 12/ 
[A] 12 
26 m 48 AC 18 42 28 - ++ 
[B] 
27 F 56 cc 27 159 34 16/ + 
(B] 12 
28 F 60 CAH +C 21 24 36 12/ - [A) 12 
29 F 56 PBC 32 40 38 12/ - 
[A] 12 
30 m 60 AC 25 36 24 17/ ... 
(c) 12 
31 M 65 PBC 17 41 37 12/ 
(A] 12 
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TMRZ 6.1 contd. 
Patient Sex Age Diagnosis Bili ALT Alb PT Ascites Ence- 






g/L sec phalo 
pathy 
32 M 59 CAH +C 29 78 36 16/ 4- + 
(B] 12 
33 m 67 AC 20 75 42 12/ - 
[A] 12 
34 m 39 cc 11 21 44 
(A] 
35 F 44 AC 21 79 46 12/ 
(A] 12 
36 M 61 CAH +C 28 39 30 12/ + 
(B] 12 
37 F 37 CPH 10 19 39 12/ + 
[A] 12 
38 F 64 CAH +C 16 24 44 12/ 
(A] 12 
39 F 42 cc 7 17 39 12/ 
[A] 12 
40 M 59 AC 40 51 29 16/ ++ +4 
[C] 12 
41 M 68 CAH +C 33 39 39 18/ + - 
[B] 12 
42 F 54 cc 26 110 36 12/ - - 
(B] 12 
43 F 62 CPH 16 28 42 12/ - - 
[A] 12 
44 M 42 AC 21 35 32 19/ + - JB] 12 
45 m 69 CAH +C 50 75 19 22/ +++ ++ 
[C] 12 
46 M 70 CC 21 23 39 12/ 
[A] 12 
47 M 52 AC 38 160 30 21/ ... + 
[C) 12 
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TABLE 6.1 contd. 
Patient. Sex Age Diagnosis Bili ALT Alb PT Ascites Ence- 
No. yrs [+ Childs umol IU g/L sec phalo 
grading] /L /L pathy 
48 m 64 cc 30 60 23 18/ 4 
[C] 12 
49 m 45 AC 11 57 38 12/ - 
[A] 12 
50 m 49 AC 17 23 41 12/ - 
[A] 12 
51 m 51 AC 19 17 31 15/ ++ 
(B] 12 
52 F 61 CC 60 190 28 19/ +++ + 
12 
53 F 39 CAH +C 53 104 26 26/ +++ ++ 
[C] 12 
54 F 62 CAH 11 26 41 12/ 
[A] 12 
Diagnoses: AC Alchoholic cirrhosis 
CC Cryptogenic cirrhosis 
PBC Primary biliary cirrhosis 
SC Sclerosingcholangitis 
CAH Chronic active hepatitis 
CPH Chronic persistant hepatitis 
PIH Post infective hepatitis 
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TkBLE 6.2. 
"ll'UNESTERASE ACrIVITIES IN PATIEWS WIM LIVER DISEASE. 
Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity 'activity activity 
IU/ML IU/ML IU/ML IU/L 
rean :6 2SD 4.58 0.88 5.04 60.5 
for Elu ;i :i :6 
homozygotes 2.32 0.508 2.54 25.5 
Patient 
number 
1 1.12 0.18 1.02 16.3 
2 9.16 1.40 8.18 97.0 
3 2.01 0.32 2.03 24.7 
4 3.38 0.55 3.14 32.0 
5 4.81 0.75 4.53 59.8 
6 3.87 0.61 3.53 39.3 
7 4.43 0.44 2.70 35.0 
8 3.22 0.53 3.12 46.6 
9 3.18 0.46 2.75 30.0 
10 3.21 0.42 2.86 35.1 
11 1.82 0.28 1.56 24.1 
12 4.56 0.65 4.20 49.5 
13 1.73 0.27 1.57 23.5 
14 7.07 1.032 7.36 70.0 
15 3.06 0.41 2.76 34.9 
16 2.80 0.39 2.98 31.2 
17 1.76 0.31 1.87 19.7 
18 1.81 0.32 1.80 23.5 
19 5.33 0.84 5.20 62.5 
20 3.11 0.60 3.19 36.4 
21 4.16 0.68 4.27 49.7 
22 0.97 0.16 0.94 16.1 
23 1.74 0.21 1.61 22.6 
24 3.84 0.68 3.89 37.5 
25 2.49 0.39 2.44 36.0 
26 1.79 0.27 1.79 24.5 
27 4.07 0.65 3.73 39.4 
28 3.13 0.50 3.02 36.3 
29 2.64 0.37 2.48 30.2 
30 1.20 0.29 1.22 14.2 
31 4.18 0.64 3.66 41.4 
32 2.55 0.45 2.86 26.7 
33 4.58 0.75 4.20 42.6 
34 6.14 0.96 5.77 56.3 
35 5.76 0.77 5.38 37.3 
36 3.06 0.45 2.83 34.2 
37 4.61 0.87 4.42 29.0 
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TABLE 6.2 contd. 
Propionyl Benzoyl Butyryl - Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
mean 2SD 4.58 0.88 5.04 60.5 
for Elu -1 =k :6 =1 
homozygotes 2.32 0.508 2.54 25.5 
Patient 
number 
38 5.28 0.82 5.03 57.3 
39 4.61 0.75 4.88 47.8 
40 1.88 0.28 1.80 24.2 
41 3.40 0.60 3.22 33.9 
42 2.50 0.43 2.72 29.8 
43 1.99 0.29 1.88 25.1 
44 2.59 0.37 2.29 29.7 
45 1.23 0.21 1.34 18.4, 
46 3.99 0.67 3.74 47.8 
47 2.04 0.34 1.90 24.8 
48 1.18 0.18 1.32 18.7 
49 2.90 0.47 2.86 27.1 
50 4.96 0.70 4.80 49.3 
51 3.90 0.57 3.40 29.0 
52 0.85 0.13 0.75 10.9 
53 1.57 0.25 1.48 17.8 
54 6.08 1.04 5.66 67.6 
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mmz 6.3. 
CHOLINESTERASE ACTIVITIES EXPRESSED AS SIANDARD DEVIATIONS 
FROM THE PlEAN 11CIR KlU - -- AND MODIFIED CEMLDS 
GRADING FCR PATIENTS WITH LIVER DISEASE. 

















meanjlSD mean-tlSD rean±lSD meantlSD 
4.58+1.16 0.88+0.25 5.04+1.27 60.5+11.7 
1 B -2.98 -2.75 -3.16 -3.5 
2 A +2.9 +2.66 +2.47 +2.86 
3 A -2.21 -2.2 -2.03 -2.81 
4 A -1.03 -1.29 -1.5 -2.24 
5 A +0.2 -0.51 -0.45 -0.06 
6 A -0.6 -1.06 -1.2 -0.67 
7 B -0.15 -1.73 -1.84 -2.0 
8 B -1.18 -1.37 -1.51 -1.09 
9 B -1.2 -1.6 -1.8 -2.39 
10 A -1.18 -1.5 -1.71 -1.99 
11 C -2.34 -2.36 -2.74 -2.84 
12 A -0.02 -0.9 -0.66 -0.87 
13 B -2.45 -2.4 -2.81 -2.91 
14 A +2.14 +0.6 +1.82 +0.74 
15 B -1.31 -1.85 -1.79 -2.01 
16 B -0.62 -1.93 -1.62 -2.30 
17 B -2.43 -2.24 -2.5 -3.20 
18 B -2.4 -2.2 -2.55 -2.90 
19 A +1.0 -0.3 -0.13 +0.15 
20 B -1.26 -1.1 -0.15 -1.81 
21 A -0.36 -0.8 -0.61 -1.85 
22 C -3.11 -2.83 -3.22 -3.48 
23 C -2.44 -2.63 . -2.46 -2.98 24 A -1.12 -0.3 --1.07 -1.80 
25 A -1.8 -1.93 -2.04 -1.93 
26 B -2.4 -2.4 -2.9 -2.82 
27 B -0.44 -0.9 -1.03 -1.65 
28 A -1.25 -1.5 -1.32 -1.90 
29 A -1.67 -2.0 -2.01 -2.38 
30 C -2.91 -2.32 -3.01 -3.63 
31 A -0.34 -0.94 -1.10 -1.5 
32 B -1.75 -1.53 -1.71 -2.65 
33 A 0 -0.52 -1.40 -0.66 
34 A +1.34 +0.30 +0.57 -0.33 
35 A +1.01 -0.43 +0.26 -1.82 
36 B -1.31 -1.69 -1.40 -2.07 
37 A +0.03 0 -0.48 -2.47 
38 A +0.6 -0.02 0 -0.25 
39 A +0.02 -0.44 -0.13 -1.00 
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TABLE 6.3 amtd. 
Patient Mod. Propionyl' Benzoyl Butyryl'Succinyl 
No. Childs thio- choline thio- choline 
grading choline choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
mean+lSD mean+lSD mean+lSD mean+lSD 
4.58+12.16 0.86+0.25 5.04-+1.27 60.6ýTll. 7 
----------- - ------ 
40 c -2.32 -2.36 -2.55 -2.85 
41 B -1.01 ; -1.1 -1.29 -2.09 
42 B -1.8 -1.77 -1.82 -2.42 
43 A -2.23 -2.32 -2.49 -2.78 
44 B -1.71 -2.01 -2.16 -2.42 
45 c -2.88 -2.63 -2.91 -3.3 
46 A -0.5 -0.82 -1.02 -1.00 
47 c -2. ý -2.12 -2.47 -2.8 
48 c -2.9 -2.75 -2.93 -3.28 
49 A -1.44 -1.61 -1.71 -2.60 
50 A +0.2 -0.71 -0.18 -0.88 
51 B -0.58 -1.22 -1.29 -2.47 
52 c -3.18 -2.95 -3.37 -3.9 
53 c -3.3 -2.48 -2.8 -3.38 
54 A +1.27 +0.63 +0.48 +0.55 
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TABLE 6.4. 
NUMBERS OF SUBJECTS WITH LOW VALUES AND THEIR 
CHILW GRADING. 






Propionylthiocholine 17 2 5 10 
Benzoylcholine 19 3 6 10 
Butyrylthiocholine 20 4 6 10 
Succinylcholine 31 6 15 10 
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Figure 6.1 
Cholinesterase activities measured using 4 substrates 
in patients with clinically graded liver disease. 
Results expressed as atandard deviations from the 
appropriate mean for El homozygotes. 
Childs grading. 
Closed-circles = grade A. 
Open circles = grade B. 















Albumin concentration and succinylcholine activity in 
patients with clinically graded liver disease. 
Childs grading. 
Closed circles = grade C 
Open circles = grade 9 
Crosses = grade A 
Shaded bars denote the respective reference intervals. 




THE SUCCINYIZWLIM-BASED ASSAY IN CHILDPEN. 
There is considerable evidence that children require more 
succinylcholine than adults to produce the same intensity 
of neuromuscular block. The intravenous dose of 
succinylcholine required for intubation varies with the 
patient's age. The recomended dose of succinylcholine for 
children ranges from 1.5 to 3 mg/kg C Letty et al 19811 
whilst adults require a dose of 1 mgAg. In addition it 
has been found that complete suppression of twitch after 
succiny1choline was present in only 19/23 children who 
received 4 mg/kg ELLLý et al. 19811 whereas 15 adults who 
received the same dose all developed complete inhibition 
of twitch [Mlts and Dillon 19671. 
The observation may be related to differences in plasma 
cholinesterase. The duration of action of succinylcholine 
has been shown to be associated with plasma cholinesterase 
activity in adults (Hodges and Harkness 1954],, 
particularly so when the enzyme activity is outside normal 
limits [Viby-Mogensen 19801. A strong negative correlation 
has . also been demonstrated between plasma cholinesterase 
activity and the duration of. succinylcholine block in. 
post-puerperal patients (Ganga et- al. 1982). Published 
work however, suggests that plasma cholinesterase is 
similar [Mirakur, Elliot and Lavery 19841 or even lower 
(Hutchinson and Widdowson 19521 in children compared with 
adults and therefore should not account for the shorter 
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duration of action of succiny1choline in children. These 
activity measurements were performed using choline esters 
other than succiny1choline and therefore do not 
necessarily reflect the ability of plasma cholinesterase 
to metabolise the drug. The object of this section of the 
project was to use the succiny1choline-based assay to 
measure cholinesterase in young children and to compare 
the results with those obtained in adults. 
7.1 Subjects. 
Plasma samples were obtained from 32 infants, 17 female 
and 15 male, age range 1 day to 14 months. No subjects 
were included having a serum bilirubin of'greater than 
100 umol/L, liver enzymes (aspartate transaminase and 
alkaline phosphatase) outside the appropriate age- 
related reference range, or who possessed a genetic 
abnormality of cholinesterase. Plasma was collected by 
pooling what remainded after the requested biochemical 
tests had been performed. Subjects fell into two groups, 
neonates (n--17) age range 1-4 days the majority of whom 
were preterm, and infants (n=15) age range 1-14 months. 
7.2 Cholinesterase activity of subjects studied. 
Succinylcholine and propionylthiocholine activities were 
measured. Results are shown in Table 7.1 and Fig. 7.1. 
Neonates had lower mean values than adults using both 
succinylcholine and propionylthiocholine substrates, 
48.7 IU/L and 3.09 IU/mL compared with 58.5 IU/L and 
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4.58 IU/ML respectively. Propionylthiocholine 
activities were similar in both infants and adults, 4.68 
and 4.58 IU/mL respectively but the mean succiny1choline 
activity of 77.1 IU/L was much higher than that in 
adults (58.5 IU/L). 
6.3 Discussicn. 
The lower mean cholinesterase activities found in 
neonates is consistant with the work of Strauss and 
Modanlou (19861 and Ehrich and Rothganger (19871. Both 
groups found reduced cholinesterase activity in preterm 
infants con-pared with full term babies or adults which 
rose to normal within a few weeks of birth. 
The infants studied here had propionylthiocholine 
activities similar to those of adults whereas their 
succinylcholine activities were higher. The results 
obtained using the succiny1choline-based assay contast 
with those obtained elsewhere using different 
substrates. zsigmond and Downs (19711 using 
benzoylcholine found lower activities in infants than 
adults. Mirakur, Elliot and Lavery (19841 using 
acetylthiocholine and Strauss and Modanlou [19861 using 
butyrylthiocholine both found that activities were 
similar in infants and adults. 
The results which I have obtained using the 
succiny1choline indicate that cholinesterase may have a 
role to play in the apparent resistance of infants to 
succinylcholine. However activities were not 
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sufficiently high to be the sole explanation for this. 
It has previously been suggested that a redistribution 
of succiny1choline from the end plate into the 
extracellular fluid (ECF) space thus avoiding breakdown 
by cholinesterase, may be the primary determinant of 
it's duration of action [Cook 19811. Since children have 
a larger ECF volume to muscle mass ratio than adults, 
this may account for their relative resistance to the 
drug. Supportive evidence for this is that the effects 
of succinylcholine are the same in children as in adults 
when the the drug is administered on the basis of body 
surface area [Walts and Dillon 1969). Another 
explanation for the shorter duration of action of 
succiny1choline in children is the reported difference 
in the apparent first order elimination rate constant 
between infants and adults [Nugent,, Laravuso and Rogers 
19791. 
Therefore these factors in addition to the increased 
cholinesterase activity in infants may all contribute to 
the apparent resistance of infants to the action of 
succinylcholine. 
From the above observations it is 'clear that the 
substrate used for the measurement of cholinesterase 
activity will alter the conclusions drawn. For example, 
on the basis of their results, using a benzoylcholine 
assay,, zsigmond and Downs [19711 suggested that the 
dose of succiny1choline could be reduced by one third in 
children of less than twelve months of age. This is not 
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supported by use of a succiny1choline-based assay which 
in contrast indicates that the dose needs to be 
increased, in line with current clinical practice. 
Therefore any extrapolation concerning sensitivity to 
succiny1choline may be misleading unless the substrate 
used reflects accurately the rate of hydrolysis of the 
drug in vivo. The succiny1choline-based assay is the one 
most likely to do this. 
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TABLE 7.1 
U TNESTERASE ACMVITIES IN NEONATES AND INFANTS. 
a) Age range 1-4 days. b) Age range 1-14 months 
Age Succinyl Propionyl Age Succinyl Propionyl 
choline thiocholine choline thiocholine 
activity activity activity activity 





















3.8 2 57.4 3.9 
2.7 4 81.1 4.4 
2.3 1 70.2 3.4 
4.0 4 127.9 
3.3 2 85.8 
3.6 5 37.5 
2.3 6 105.2 
4.1 2 89.1 5.0 
5.1 1 59.2 5.0 
2.0 1 85.8 5.4 
1.7 3 63.0 4.7 
14 60.7 4.3 
4 113.2 7.7 
3.1 5 51.6 5.4 
2.5 8 68.7 4.3 
2.8 
mean 48.74 3.09 
SD 14.3 0.95 
mean 77.09 4.86 
SD 24.03 1.12 







w 80- z D 












































Cholinesterase activities in neonates & infants 
measured using succinylcholine and propionylthiocholine 
as substrates. 
Shaded bars = reference intervals for adult Elu 
homozygotes for each method. 




CHDLTNESTERASE MEASUREMENTS IN ANIM" 
Cholinesterase occurs throughout the animal kingdom though 
with different physicochemical and biochemical properties. 
Despite this extensive distribution, the natural substrate 
and function of the enzyme is not known. Nonetheless 
cholinesterase measurements do have practical 
significance. They have been used to assess the degree of 
exposure to organophosphates (Crookshank and Palmer 19781 
and in experiments to provide information concerning the 
effect of succiny1choline on animals Wright et al. 
19811. 
There is wide species variation in response to 
succinylcholine. Domestic animals have been most 
extensively studied. The horse, pig and cat are relatively 
resistant whereas dogs, sheep and cattle are sensitive to 
even small doses [Hall and Clarke 19831. 
Since hydrolysis by cholinesterase is the major factor in 
recovery from the effects of succiny1choline attempts have 
been made to correlate species sensitivity with plasma 
cholinesterase activity. The ability of plasma 
cholinesterase to hydrolyse butyrylthiocholine can be used 
to predict sensitivity to succiny1choline in man but it 
has not been of value in animals (Hansson 1957, Wright et 
al. 19811. It is possible that in species other than man 
the rate of hydrolysis of butyrylthiocholine does not 
parallel that of succiny1choline and if Sol a 
/ 
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succiny1choline-based assay could give a better index of 
the species ability to hydrolyse the drug in vivo. The 
object of this section of the thesis was to investigate 
this hypothesis. 
8.1 Blood samples and methods. 
Blood samples from animals were obtained as follows, 
a) Dogs and cats from a local veterinary surgeon. 
b) Cattle, pigs and sheep from Mr M. S Bain, Veterinary 
Investigation Centre, Riseholmep Lincolnshire. 
c) Horses from Dr M. S Moss, Horse Racing Forensic 
Laboratories Ltd.,, Newmarket, Suffolk. 
d) Chickens from Professor Kerr, Department of Animal. 
Physiology and Nutrition, University of Leeds. 
e) Zoo animals from Dr. C Hawkey, Wellcome Research 
Laboratories, London Zoo, Regents Park, London. 
Samples from dogs and cats were collected and separated 
daily then stored at -20 
0 C. All other samples were 
collected, separated and stored (at -20 
0 C) by the 
laboratories concerned. 
Cholinesterase activity was measured using 
propionylthiocholine, benzoylcholinerbutyrylthiocholine 
and succiny1choline as substrates. 
8.2 Studies on domestic animals. 
The following danestic species were studied, pigs (two 
breeds Landrace and Large White), dogs, cats, cattle, 
sheep, chickens and horses. Cholinesterase, activities 
were measured using all four substrates except with 
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specimens f rom cats. These were small and so only 
propionylthiocholine and succiny1choline activities were 
performed. Results are shown in'Fig. 8.1 and Table 8.1. 
Dogs and horses demonstrate highest cholinesterase 
activity with butyrylthiocholine as the substrate 
whereas chickens show highest activity with 
propionylthiocholine. The ruminants studied had low 
cholinesterase activities with all substrates. 
In any attempt to correlate cholinesterase activity with 
response to succiny1choline it is first necessary to 
find a comparable dose of drug in all species. This is 
difficult since quoted doses result in different 
durations of action depending on the requirement in a 
particular animal. Ideally evidence is needed for the 
amount of succiny1choline which would paralyse each 
species for the same time. I did not have the facilities 
to perform such work so an alternative approach was 
taken. 
Tolerance to succiny1choline has been estimated 
experimentally for cattle, dogs, pigs (Landrace) and 
horses (Hansson 1957]. The dose required to produce 
rmscle fasiculation without the loss of the ability to 
stand was used as a reproducible end-point. In man an 
infusion of 28-43 ug/kg/min produces muscle relaxation 
[Laurence and Bennett 1980). Approximately half this 
dose produces muscle fasiculation,, as seen when 
succiny1choline is used as an adjunct to ECT therapy 
Dept. of Anaesthesia, Leeds General Infirmary, personal 
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communication]. Cholinesterase activities measured using 
the four substrates were plotted against the data 
obtained from Hanssen's study and that for man. Results 
are shown in Figs. 8.2 and 8.3. 
Results demonstrate that cholinesterase activity 
measured using succiny1choline as the substrate is 
directly proportional to tolerance to the drug whereas 
those obtained using any of the other substrates there 
show no such relationship. 
7.3 Studies on zoo animals. 
Cholinesterase activities using all four substrates are 
shown in Table 8.2. In addition they are expressed as a 
percentage of the mean of the appropriate reference 
range for human Elu homozygotes, to aid comparison. 
of the orders studied, Aves, Cetacea and Proboscidea 
contained only one animal each so no conclusions can be 
drawn. Of the remaining orders cholinesterase activities 
measured using propionylthiocholine, benzoylcholine and 
butyrylthiocholine are similar, Man> Reptila> Primata> 
Perissodactylaý Carnivora> Artiodactyla. whereas using 
succinylcholine there is a different pattern of 
hydrolysis, Primata> Man> Carnivora> Perissodactyla> 
Reptila> Artiodactyla. 
B. 4 Discumion. 
The substrate specificity patterns of plasma 
cholinesterases from different species are diverse. Some 
show maximum activity against butyrylthiocholine and 
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some against propionylthiocholine. Ruminants 
demonstrated little activity using any of the 
substrates. These results agree with those of Myers 
[19481. 
Cholinesterase activities plotted against a measure of 
tolerance to succinylcholine show that only with 
succinylcholine as the assay substrate does plasma 
cholinesterase correlate with the species ability to 
hydrolyse the drug. This is at odds with the results of 
Hansson [1957] who did not show any relationship between 
succinylcholine hydrolysis in vitro and the species 
sensitivity to the drug. However Hansson's 
succiny1choline-based assay was relatively insensitive 
and gave undetectable hydrolysis rates for 
cholinesterase f rom the plasma of cattle and dogs. 
Dogs have a prolonged relaxation when treated with 
succiny1choline in a dose which would be appropriate foý 
a human [Merin 19861. It was initially thought this was 
due to a different plasma cholinesterase in canines but 
it has not been substantiated [Hall and Lehmann 1953 and 
Hansson 19571. Results presented here show that dogs 
have lower cholinesterase than humans, whichever 
substrate is used for it's assay. The contrast however 
is most marked when results obtained using 
succiny1choline are compared. The mean activity in dogs 
was found to be 14.8% that of the mean activity in 
humans when succinylcholine was used as the assay 
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substrate. With other substrates the mean activities 
were 40-49% that of humans. muscle relaxation in dogs is 
readily achieved following administration of 0.1-0.2 mg 
succiny1choline Ag of body weight. This is 10-20% of 
that required in humans. This observation can be 
reco nciled with plasma cholinesterase activity only when 
the latter is measured using succinylcholine. 
The in vitro hydrolysis of succiny1choline by 
cholinesterase appears to parallel it's breakdown in 
vivo in different domestic animal species whereas the 
hydrolysis of other substrates does not. This emphasises 
the importance of using such a method in the 
investigation of all animal species, but especially in 
in wild animals where experience with succiny1choline 
is limited. 
Wright and colleagues [19811, in an attezpt to explain 
the susceptibility of different species to 
succinylcholine, measured cholinesterase activity 
against butyrylthiocboline in 26 wild animal species 
from South Africa. They could not explain differences in 
susceptibility using butyrylcholine hydrolysis or use 
it to predict effective doses of the drug. 
In the present study 33 species from 9 orders were 
studied. The hydrolysis of three additional substrates 
as well as butyrylthiocholine was examined and results 
confirm findings with respect to wide species variation 
in cholinesterase activities [Wright et al 19811. Some 
species having low or undetectable activities whilst 
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others have levels comparable with the highest seen in 
man. 
Using propionylthiocholine, benzoylcholine and 
butyrylthiocholine as assay substrates the pattern of 
cholinesterase activities of the different orders 
studied was similar. Highest activities occur in Man and 
the lowest. in Artiodactyla. Succinylcholine hydrolysis 
patterns were different. However it is difficult to 
assess whether this difference means it can be used to 
predict the susceptibility of different species to it's 
muscle relaxant properties. 
In domestic species the doses of succinylcholine used 
are well documented both clinically and experimentally 
[Hall and Clarke 19831. Such information is not 
available on wild species. Where dose levels are 
documented they concern single or low numbers of animals 
and no durations of paralysis are given [Buechner, 
Harthoorn and Lock 1960a and 1960b) thus information is 
anecdotal and not readily comparable. 
The only large cohort of animals these workers studied 
was a group of 50 Adenota kob thomasi (antelope). A 
dose which effectively immobilised all animals was 0.35 
mg/kg approximately one third of the muscle relaxant 
dose in man. The antelope is of the order Artiodactyla 
and in the present study only cholinesterase activities 
measured using succiny1choline are of a magnitude 
compatible with this clinical observationj being 10-30% 
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of that seen in man. 
I 
With other substrates, activities 
were undetectable or only up to 5% of values in man. 
Clearly the sensitivity of the antelope, like that of 
the domestic species studied, can be predicted solely by 
use of the succinylcholine-based- assay. 
The work presented in this chapter confirms the 
hypothesis that cholinesterase activity measured using 
succiny1choline rather than conventional assay 
substrates, gives a better index of the ability of 
different species to hydrolyse the drug in vivo. 
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TABLE 8.1. 
1. PIGS (Larxkace) 
ACTIVITIES IN DODMIC ANIMALS. 
No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
1 0.32 0.01 0.26 30.5 
2 0.34 0.01 0.27 29.9 
3 0.31 0.01 0.24 25.9 
4 0.34 0.02 0.21 34.6 
5 0.23 0.02 19.9 
6 0.28 0.02 0.27 31.5 
7 0.29 0.02 0.27 39.8 
8 0.32 0.02 0.27 
9 0.35 0.02 Oý30 38.2 
10 0.39 0.01 0.34 43.2 
11 0.27 0.02 0.27 36.0 
12 0.34 0.03 0.26 31.5 
13 0.38 0.04 0.33 22.8 
14 0.23 0.03 0.24 16.6 
15 0.43 0.05 0.36 64.4 
16 0.33 0.04 0.35 49.4 
rean 0.322 0.023 0.288 34.28 
lSD 0.054 0.012 0.047 12.06 
2. PIGS (Large Miite) 
No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
1 0.42 0.07 0.51 58.7 
2 0.27 0.02 0.26 19.1 
3 0.32 0.02 0.32 50.7 
4 0.38 0.05 0.36 24.1 
5 0.41 0.04 0.43 70.5 
6 0.36 0.04 0.32 50.2 
7 0.41 0.05 0.33 68.3 
8 0.38 0.03 0.39 56.4 
9 0.35 0.05 0.30 58.5 
10 0.22 0.02 0.25 49.2 
11 0.34 0.02 0.31 45.7 
12 0.20 0.02 0.15 51.3 
13 0.33 0.03 0.30 44.9 
14 0.56 0.06 0.60 80.0 
rwan 0.351 0.037 0.345 51.97 
1SD 0.086 0.017 0.112 16.32 
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3. Do Gs 
No. Propionyl Benzoyl Butyryl suc6inyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
1 1.94 0.35 2.2 3.9 
2 1.73 0.30 1.9 3.3 
3 1.75 0.34 2.2 6.3 
4 2.46 0.44 3.0 8.9 
5 2.33 0.39 9.1 
6 2.1 8.2 
7 7.55 13.5 
8 0.81 7.2 
9 1.8 8.4 
10 2.45 8.6 
11 1.0 4.0 
12 1.6 11.6 
13 1.3 ND 
14 0.97 19.2 
mean 2.127 0.364 2.325 8.01 
1SD 1.65 0.053 0.427 4.75 
4. CA M 
No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine -choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
1 0.83 0.11 1.18 ND 
2 0.79 9.0 
3 1.7 0.16 10.7 
4 1.2 6.4 
5 4.95 8.0 
6 0.62 10.7 
7 5.2 
8 0.77 8.2 






insufficient sample for analysis' 




No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/mL IU/mL IU/L 
1 1.23 0.038 0.71 11.4 
2 1.27 0.046 0.76 6.8 
3 1.14 0.039 0.65 10.2 
4 1.13 0.050 0.62 13.2 
5 1.49 0.048 0.87 10.8 
6 1.55 0.053 0.90 16.0 
7 1.36 0.046 0.81 13.8 
8 1.11 0.041 0.63 9.9 
9 1.21 0.034 0.69 12.6 
10 1.50 0.037 14.4 
11 1.52 0.041 0.88 
mean 1.319 0.043 0.752 11.91 
lSD 0.171 0.006 0.107 2.65 
6. Ck TTLE 
No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/mL IU/Ml IU/L 
1 0.11 ND ND ND 
2 0.074 ND UD ND 
3 0.068 ND ND ND 
4 0.063 ND ND 2.5 
5 0.068 ND ND ND 
6 0.055 ND ND 2.5 
7 0.068 ND ND ND 
8 0.032 ND ND 2.9 
9 0.039 ND ND ND 
10 0.037 ND ND ND 
11 0.033 ND ND 3.5 
12 0.033 ND ND ND 
mean 0.057 0.95 
lSD 0.023 1.42 
insufficient sample for analysis 
ND no cholinesterase activity detected 
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7. 1 - 
No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
1 0.047 ND ND 3.0 
2 0.063 ND ND 2.2 
3 0.061 ND ND 3.5 
4 0.053 ND ND ND 
5 0.061 ND ND 2.2 
6 0.058 ND ND 4.8 
7 0.028 ND ND ND 
8 0.043 ND ND ND 
9 0.011 ND ND ND 
mean 0.047 1.74 
lSD 0.018 1.82 
ND no cholinesterase activity detected 
8. 
No. Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activtiy activity 
IU/ML IU/ML IU/ML IU/L 
1 3.68 0.25 4.15 33.0 
2 5.15 0.31 5.43 40.0 
3 2.71 0.19 3.37 25.5 
4 4.68 0.30 5.03 39.2 
5 4.50 0.23 4.95 33.9 
6 5.24 0.29 5.73 36.9 
7 3.98 0.27 4.49 33.3 
8 4.57 0.27 4.61 32.4 
9 3.07 0.28 3.64 23.8 
mean 4.18 0.266 4.46 33.1 
lSD 0.88 0.037 0.78 5.5 
4: 2 
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TABLE 8.2. MMINESTERASE ACTIVITIES IN ZOO ANIMALS. 
Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
Figure in brackets = result expressed as % of 
appropriate mean human reference range (see 
end of table) 
Onager 0.99(21.6) 0.12(13.6) 1.12(22.2) 13.4(22.9) 
Donkey -4.55(99.3) 0.55(62.5) 5.70(124.4) 36.1(61.6) White 
Rhino 1.36(29.7) 0.10(12.5) 1.73(34.3) 26.4(45.1) 
Onager 1.45(31.7) 0.11(12.5) 1.68(33.3) 15.0(25.6) 
--- - ------------ 
mean 2.09(45.6) 0.22(25.3) 2.56(53.5) 22.7(38.8) 
----------------------------- - 
CARRIVCRA 
Kinkajou 12.0(262.9) 34.0(677) , 
76.9(131)E 
Serval 2.69(58.7) 3.9(76.8) 57.7(98.4) 
Jaguar 1.25(27.3) 1.5(29.8) 44.9(76.6) 
Cheetah 0.34( 7.4) 0.3( 6.3) 34.1(58.2) 
Spectacled 
bear 0.28( 6.1) 0.2( 4.2) 11.5(19.6) 
Spectacled 
bear 0.30( 6.6) 0.2( 4.4) 15.7(26.8) 




Viper- 0.29( 6.3) 0.29( 5.7) 9.6(16.4) 
Aldabra giant 
Tortoise 0.03( 0.7) 0.01( 0.2) 12.0(20.5) 
Iguana. 3.65(79.7) 2.65(52.6) 9.2(15.7) 
Iguana 11.3 (246.7) 13.21(262) 35.4(60.4) 













duck 0.39( 8.5) 0.07(7.9) 0.35( 6.9) 11.1(18.9) 
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TABLE 8.2 contd. 
Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/rL IU/ML IU/IPL IU/ML 
Figure in brackets = result expressed as % of 
mean of appropriate hurran reference range (see end 
of table) 
AIMCDACTYIA 
Red Deer 0.06( 1.3) 
Gaur 0.14( 3.1) 
Goat 0.14( 2.9) 
Guanaco 0.13( 2.8) 
Kudu 0.04( 0.9) 
Fallow 
Deer 0.04(l. 0) 
Fallow 
deer 0.066(l. 4) 
Eland 0.085(l. 9) 
Mouflon 0.10 (2.2) 
Scimitar 
horned 
0.04( 4.5) 0.02( 0.5) 6.8(11.6) 
ND 0.07(l. 3) 15.4(26.3) 
0.04( 4.5) 0.02( 0.5) 6.7(11.4) 
ND 0.05( 1.1) 7.7(13.1) 
ND 0.03( 0.5) 6.0(10.2) 
ND 0.07( 1.3) 7.3(12.4) 
ND 0.013(0.3) 17.0(29.0) 
ND 0.107(2.1) 17.0(29.0) 
ND 0.020(0.4) 10.4(17.4) 
onyx 0.05 (1.1) ND 0.016(0.3) 12.7(21.7) 
Yak 0.07(l. 5) ND 0.013(0.3) 13.5(23.0) 












ND 0.02(0.4) 47.9(81.7) 
ND 0.045(0.9) 7.0(11.9) 
162 
TABLE 8.2 contd. 
Propionyl Benzoyl Butyryl Succinyl 
thiocholine choline thiocholine choline 
activity activity activity activity 
IU/ML IU/ML IU/ML IU/L 
Figure in brackets = result expressed as % of 
mean of appropriate human reference range (see 
end of table). 
=71ý=. ========================================= 
Baboon 4.2(91.7) 0.85(96.6) 7.01(139.1) 89.7(153.1) 
Sacred 
Baboon 3.79(82.8) 0.88(100) 4.9(97.2) 101.9(173.9) 
Vervet 1.02(22.3) 0.16(18.2) 1.53(30.4) 50.0(85.3) 
Green 
Monkey 0.08(l. 7) ND 1.53(30.4) 15.4(26.3) 
Chimp 5.65(123.4) 0.95(108) 6.35(126) 78.0(133.1) 
Chimp 5.4(117.9) 0.91(103.4) 5.95(118.1) 75.0(128) 
Assamese 
Macaque 2.01(43.9) 0.41(46.6) 2.86(56.7) 80.8(137.9) 
Sykes 
monkey 2.67(58.3) 0.47(53.4) 4.18(82.9) 88.5(151.0) 
L'Hoest's 
monkey 4.42(96.5) 0.64(72.7) 4.41(87.5) 100(170.6) 
Roloway 
monkey 0.28(5.8) 0.05(5.7) 0.45(8.1: ) 19.2(32.8) 
Patas 
monkey 0.42(9.2) 0.05(5.7) 0.68(13.5) 26.9(45.9) 
mean 2.72(59.4) 0.45(55.5) 3.62(71.8) 65.9(112.5) 
excluded because of marked difference from rest of 
group 
insufficient specimen for analysis 
ND no cholinesterase activity detected 
Mean cholinesterase activity for human Elu hawzygotes. 
Propionylthiocholine activity 4.58 IU/mL 
Benzoylcholine activity 0.88 Iu/mL 
ButYrYlthiocholine activity 5.04 IU/mL 
[Evans and Wroe 1978] 










Figure 8. la 
CATTLE SHE EP 
Cholinesterase activities in domestic species expressed 
as % of the mean of appropriate human reference range. 

















Figure 8. lb 
Cholinesterase activities in domestic species expressed 
as % of the mean of appropriate human reference range. 
M= Propionythiocholine activity 
F22 = Benzoylcholine activity 
ED = ButyrIthiocholine activity 
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The relationship between cholinesterase activity 
reasured using conventional substrates and tolerance to 
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The relationship between cholinesterase activity 
measured with succiny1choline as the substrate and 






l. ' A simple, precise "reaction rate" assay for plasma 
cholinesterase based on a succiny1choline substrate has 
been developed. It employs only readily available 
reagents and equipment and therefore is suitable for use 
in any routine clinical chemistry laboratory. 
2. - It's ability to define individuals at risk of 
succiny1choline sensitivity - and identify those who had 
experienced apnoea was assessed and it performed better 
than a propionylthiocholine-based assay, previously shown 
to be the best available for this purpose [Evans and Wroe 
19781. 
3. It was applied to genotypically normal patients with 
apparently abnormal reactions to succiny1choline in an 
attempt to identify" previously unrecognisedo, abnormal 
forms of'cholinesterase which could hydrolyse conventional 
assay substrates but not succinylcholine. No such variants 
of cholinesterase were identified and it was concluded 
that if these forms exist their numbers are small. 
3. The kinetics of the succinylcholine-cholinesterase 
interaction were studied and results showed that the 
hydrolysis of succinylcboline by cholinesterase does not 
obey Michaelis-Menten kinetics. The observed kinetics were 
consistant with previous observations, using other 
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substrates, that cholinesterase has two active sites one 
with high the other with low Km and Wax values. The 
average value for the Kml site (the site responsible for 
the hydrolysis of succiny1choline at pharmacological 
concentrations) for usual cholinesterase was 92.4 umol/L 
and for the atypical enzyme was 6.922 mmol/L which are 
consistant' with clinical observations of reactions to 
succinylcholine. 
4. Serum cholinesterase was measured in 54 subjects with 
clinically graded liver disease. The succiny1choline-based 
assay was compared with three conventional assays using 
propionylthiocholine, benzoylcholine and 
butyrylthiocholine. All assays identified patients with 
severe liver disease but the succiny1choline-based assay 
identified more with moderate/mild disease and therefore 
is the most clinically useful. 
5. The succiny1choline-based assay was applied to plasm 
from neonates and infants in an attempt to clarify reasons 
for their relative resistance to succinylcholine. 
Premature neonates were found to have lower cholinesterase 
activities than adults. This is in agreement with other 
workers reporting a transient cholinesterase deficiency in 
this group. The infants were found to have higher mean 
cholinesterase activities than adults when measured using 
succiny1choline as the substrate. This may contribute to 
their relative resistance to the drug but the range of 
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values observed make it unlikely that this is the only 
factor. 
6. Cholinesterase measurements made in a variety of animal 
species using a range of substrates including 
succinylcholine indicate that there is a diverse pattern 
of substrate specificity. However only when 
succiny1choline is used as the substrate for assay of 
cholinesterase does enzyme activity correlate with 
tolerance to it's muscle relaxant properties. 
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